var title_f37_60_38848="Levofloxacin: Patient drug information";
var content_f37_60_38848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Levofloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/63/24564?source=see_link\">",
"       Levofloxacin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/32/13830?source=see_link\">",
"       Levofloxacin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10802 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38848=[""].join("\n");
var outline_f37_60_38848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/63/24564?source=related_link\">",
"      Levofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/32/13830?source=related_link\">",
"      Levofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38849="Debridement and primary repair of esophageal perforation";
var content_f37_60_38849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Debridement and primary repair of esophageal perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A depicts the exposed mucosa and muscular layer of the perforated esophagus. Devitalized tissue is sharply debrided.",
"    <br>",
"     Figure B depicts the longitudinal extension of the muscular defect to completely expose the mucosal defect. The extension of the muscularis can be performed superior and inferior to the perforation.",
"     <br>",
"      Figure C depicts the primary repair of the debrided esophageal perforation. The closure is performed in two layers.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38849=[""].join("\n");
var outline_f37_60_38849=null;
var title_f37_60_38850="Patient information: Implantable cardioverter-defibrillators (The Basics)";
var content_f37_60_38850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15665\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/32/16899\">",
"         ICDs and pacemakers compared",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/49/6931\">",
"         Patient information: Pacemakers (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/54/13154\">",
"         Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?22/56/23427\">",
"         Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/16/20741\">",
"         Patient information: Pacemakers (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Implantable cardioverter-defibrillators (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/implantable-cardioverter-defibrillators-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H555736308\">",
"      <span class=\"h1\">",
"       What is an implantable cardioverter-defibrillator?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An implantable cardioverter-defibrillator, also called an &ldquo;ICD,&rdquo; is a device that goes under a person&rsquo;s skin near his or her heart (",
"      <a class=\"graphic graphic_figure graphicRef67053 \" href=\"mobipreview.htm?16/32/16899\">",
"       figure 1",
"      </a>",
"      ). An ICD can sense and treat certain abnormal heartbeats.",
"     </p>",
"     <p>",
"      A person&rsquo;s heart needs to beat normally in order to pump blood to the brain and rest of the body. But sometimes, a person&rsquo;s heartbeat can suddenly become abnormal. The heartbeat could be too slow, too fast, or out of rhythm.",
"     </p>",
"     <p>",
"      Some abnormal heartbeats are dangerous, because they can prevent the heart from pumping blood to the brain and rest of the body. A &ldquo;cardiac arrest&rdquo; is when an abnormal heartbeat prevents the heart from pumping blood normally. A cardiac arrest can happen without warning, and can cause death if it is not treated right away.",
"     </p>",
"     <p>",
"      An ICD can treat the abnormal heartbeats that can lead to a cardiac arrest. People who have an ICD have a greater chance of surviving a cardiac arrest.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736315\">",
"      <span class=\"h1\">",
"       Who might need an ICD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might need an ICD if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a condition that can cause abnormal heartbeats",
"       </li>",
"       <li>",
"        Have had one or more episodes of abnormal heartbeats",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736322\">",
"      <span class=\"h1\">",
"       How does an ICD work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ICD works to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Sense abnormal heartbeats",
"       </li>",
"       <li>",
"        Give the heart one or more electrical shocks if the heartbeat becomes abnormal. This can get the heart to beat normally again.",
"       </li>",
"       <li>",
"        Record abnormal heartbeats so that a doctor can see how a person&rsquo;s heart has been beating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736329\">",
"      <span class=\"h1\">",
"       What does an ICD look like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ICD has 2 parts:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Battery &ndash; This sits under the skin in the upper chest. When the ICD senses an abnormal heartbeat, the battery creates an electrical shock or shocks that travel through wires to the heart.",
"       </li>",
"       <li>",
"        Wires, also called &ldquo;leads&rdquo; &ndash; These go from the battery through a vein (blood vessel) and into the heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736336\">",
"      <span class=\"h1\">",
"       Can there be side effects to having an ICD?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor will talk with you about the different side effects that can occur. Side effects can occur when a doctor puts in an ICD. People who have had an ICD for a long time can also have side effects. But most people do not have any side effects from having an ICD.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736343\">",
"      <span class=\"h1\">",
"       What should I do after my ICD treats an abnormal heartbeat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your ICD gives you a shock (you will probably feel it), let your doctor know. He or she will look at the record of your heartbeats and might decide to make changes to the way your ICD works.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736350\">",
"      <span class=\"h1\">",
"       Do people with an ICD need other treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes, people with an ICD will need other treatment. This can include medicines or procedures.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736357\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, talk with your doctor or nurse. Many women with an ICD are able to have a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736364\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with an ICD have a normal life. But you will need to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Check your ICD on a regular basis to make sure that it works &ndash; Many people can check their ICD from their home, using either their phone or computer.",
"       </li>",
"       <li>",
"        Talk to your doctor about driving &ndash; Many states do not allow people to drive for some amount of time after they have an ICD put in or after they get a shock from their ICD. Your doctor will tell you how long you need to wait before you drive again.",
"       </li>",
"       <li>",
"        Avoid certain electric or magnetic sources &ndash; People who have an ICD need to avoid certain electric or magnetic sources or equipment. Your doctor will tell you which ones are safe for you to be near, and which ones you should avoid. For example, some people with an ICD should not walk through a metal detector at the airport. (People who cannot walk through a metal detector can have a security search by hand instead.)",
"       </li>",
"       <li>",
"        Let all of your doctors and nurses know that you have an ICD &ndash; Some procedures and tests are safe for people with an ICD, but others are not. For example, people with an ICD should not have a type of imaging test called an MRI scan. Most doctors recommend that people wear a medical bracelet letting others know that they have an ICD.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people who have an ICD feel worried or sad. If you feel worried or sad, let your doctor or nurse know so that he or she can help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555736060\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=see_link\">",
"       Patient information: Pacemakers (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/54/13154?source=see_link\">",
"       Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/56/23427?source=see_link\">",
"       Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=see_link\">",
"       Patient information: Pacemakers (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/60/38850?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15665 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38850=[""].join("\n");
var outline_f37_60_38850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736308\">",
"      What is an implantable cardioverter-defibrillator?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736315\">",
"      Who might need an ICD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736322\">",
"      How does an ICD work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736329\">",
"      What does an ICD look like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736336\">",
"      Can there be side effects to having an ICD?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736343\">",
"      What should I do after my ICD treats an abnormal heartbeat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736350\">",
"      Do people with an ICD need other treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736357\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736364\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555736060\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/32/16899\">",
"      ICDs and pacemakers compared",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/16/20741?source=related_link\">",
"      Patient information: Pacemakers (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/49/6931?source=related_link\">",
"      Patient information: Pacemakers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/54/13154?source=related_link\">",
"      Patient information: Radiofrequency catheter ablation for the heart (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/56/23427?source=related_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38851="Lentigines after laser therapy";
var content_f37_60_38851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55782&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Lentigines on the dorsal hands after laser treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lentigines on the dorsal hands resolved after a single treatment with a Q-switched alexandrite laser.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38851=[""].join("\n");
var outline_f37_60_38851=null;
var title_f37_60_38852="AIP plasma cells Light HP";
var content_f37_60_38852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55993&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power (200x) view of a pancreas biopsy in a patients with autoimmune pancreatitis showing an infiltrate composed primarily of plasma cells admixed with lymphocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Russell Dorer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38852=[""].join("\n");
var outline_f37_60_38852=null;
var title_f37_60_38853="Esoph adenocarcinoma Light";
var content_f37_60_38853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low-power photomicrograph shows an adenocarcinoma that developed in a patient with Barrett's esophagus. There is marked distortion of the glandular architecture that makes it difficult to ascertain where one gland ends and another begins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc. at 1-800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38853=[""].join("\n");
var outline_f37_60_38853=null;
var title_f37_60_38854="Female levator muscle 3D form";
var content_f37_60_38854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Female levator muscles: three-dimensional form",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 466px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Digitally enhanced three-dimensional reconstructions of the female pelvic floor from a magnetic resonance image of the pelvis in a normal nulliparous 23-year-old woman.",
"    <br/>",
"    (A) Anterior view of the levator ani muscle with normal resting tone.",
"    <br/>",
"    (B) Sagittal view of the levator ani muscle, bony pelvis, vagina, and rectum.",
"    <br/>",
"    (C) Posterior view of the levator ani muscle, obturator internus muscles, and bony pelvis.",
"    <br/>",
"    (D) Lithotomy view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38854=[""].join("\n");
var outline_f37_60_38854=null;
var title_f37_60_38855="Causes of chronic wrist pain in children and adolescents";
var content_f37_60_38855=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of chronic wrist pain in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     D Scott Upton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38855/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/60/38855/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to the wrist are common in children, adolescents, and young adults. A thorough understanding of the anatomy of the growing wrist, common wrist injuries, and other causes of wrist pain are essential to accurate diagnosis and appropriate treatment.",
"   </p>",
"   <p>",
"    Causes of chronic wrist pain in children and adolescents include acute injuries that have failed to heal, overuse syndromes, and pain unrelated to trauma. Traumatic and nontraumatic causes of chronic wrist pain in children and adolescents will be presented here. Acute wrist injuries, wrist anatomy, and the evaluation of wrist pain in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link\">",
"     \"Overview of acute wrist injuries in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32440?source=see_link\">",
"     \"Evaluation of wrist pain and injury in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERUSE INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overuse injuries, which include tendonitis, distal radius physeal stress reaction, Kienb&ouml;ck's disease, chronic DRUJ and TFCC injury, neuropathy, and impaction syndromes, are more common among adolescents than younger children (",
"    <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"     table 1",
"    </a>",
"    ). Overuse injuries have insidious symptoms; they frequently are identified when an acute injury is superimposed at the site of previous microtrauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/1\">",
"     1",
"    </a>",
"    ]. Risk factors for overuse injuries in children and adolescents include rapid intensification of training, muscle-tendon imbalance, poor conditioning before training, deficient nutrition, associated chronic disease, and periods of rapid growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Tendon injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendonitis involves inflammation of the tendon or its synovial sheath. Tendonitis is caused by repetitive motion or impact stress (eg, in gymnastics, racquet sports). Clinical features include pain that is exacerbated by activity and can be reproduced by passive stretching of the affected tendon or active contraction of the associated muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/3\">",
"     3",
"    </a>",
"    ]. Radiographs are not usually necessary in the evaluation of patients with tendonitis, but may be helpful in excluding other injuries or conditions.",
"   </p>",
"   <p>",
"    Treatment strategies for tendonitis include rest, bracing, antiinflammatory agents, glucocorticoid injections, and correcting the training error or biomechanical etiology. Sports activity can be gradually resumed once symptoms have resolved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      De Quervain's &ndash; De Quervain's tenosynovitis involves the sheath of the abductor pollicis longus and the extensor pollicis brevis at the level of the radial styloid. De Quervain's tenosynovitis occurs in individuals who golf, fly fish, or play racquet sports. The clinical manifestations, diagnosis, and treatment are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27270?source=see_link\">",
"       \"de Quervain's tenosynovitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ECU tendonitis &ndash; Extensor carpi ulnaris (ECU) tendonitis is seen in participants of sports that require forceful wrist extension (eg, racquet sports, golf, rowing) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Inflammation occurs in the sixth dorsal extensor compartment as the ECU tendons pass in a groove along the ulna [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Clinical features of ECU tendonitis include tenderness and swelling over the ECU tendon in the ulnar groove and pain that is exacerbated by wrist extension against resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Relief of pain with",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      injection into the ECU sheath can confirm the diagnosis if confirmation is necessary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Initial treatment involves rest, immobilization with a neutral wrist brace, modification of activities, and oral antiinflammatory agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ]. Glucocorticoid injection into the sheath is a reasonable second-line option. Failure to improve with these treatments may indicate additional pathology and further evaluation is warranted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ]. Surgical decompression with division of the sub sheath housing the ECU tendon is the final treatment option.",
"     </li>",
"     <li>",
"      ECU subluxation &ndash; ECU subluxation results from rupture or attenuation of the ECU sub sheath, usually due to sudden wrist flexion under ulnar deviation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ]. It may occur in golfers, weight lifters, rodeo riders, tennis players, and baseball players [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5,8\">",
"       5,8",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Patients complain of dorsal ulnar wrist pain and \"snapping\" that are increased with rotation of the forearm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/8\">",
"       8",
"      </a>",
"      ]. On examination, the ECU tendon can be observed subluxing over the ulnar styloid when the patient deviates the wrist ulnarly in full supination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ]. ECU subluxation responds well to immobilization; surgical reconstruction is rarely needed.",
"     </li>",
"     <li>",
"      FCR tendonitis &ndash; Flexor carpi radialis (FCR) tendonitis presents with pain at the area of the FCR with resisted flexion or passive wrist extension (",
"      <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"       figure 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Initial treatment involves rest, immobilization in a neutral wrist brace, antiinflammatory agents, and stretching exercises. Glucocorticoid injection is slightly more difficult since the FCR is in close proximity to the radial artery. In prolonged cases, surgery may be indicated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FCU tendonitis &ndash; The flexor carpi ulnaris (FCU) tendon partially fans out in its distal insertion on to the pisiform before attaching to the base of the fifth metacarpal (",
"      <a class=\"graphic graphic_figure graphicRef69097 \" href=\"mobipreview.htm?1/31/1527\">",
"       figure 1",
"      </a>",
"      ). Flexor carpi ulnaris (FCU) tendonitis can result from repetitive motion or pisotriquetral compression. Compression occurs from loading, hitting with an open fist (eg, in karate), or trauma (eg, from the end of a racquet, stick, or club at the end of the swing) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The characteristic feature of FCU tendonitis is pain in the region of the FCU tendon with resisted wrist flexion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6\">",
"       6",
"      </a>",
"      ]. Pain with compression of the pisotriquetral complex is more suggestive of pisotriquetral arthritis or contusion. Point tenderness over the hamate is more suggestive of hamate fracture. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Hamate fractures'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Plain radiographs are normal in patients with FCU tendonitis. They may show degenerative changes at the pisotriquetral joint in patients with pisotriquetral arthritis or fractures of the hook of the hamate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of acute wrist injuries in children and adolescents\", section on 'Hamate fractures'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Conservative management with rest, a neutral wrist brace, and stretching is usually successful for FCU tendonitis secondary to repetitive motion or pisotriquetral compression. Subperiosteal excision of the pisiform can be curative for recalcitrant cases of pisotriquetral arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intersection syndrome &ndash; Intersection syndrome results from repetitive wrist extension against resistance (eg, rowing, weight lifting) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. Pain and tenderness are localized at the point of intersection of the abductor pollicis longus, extensor pollicis brevis, and the extensor carpi radialis. Active extension of the wrist and thumb against resistance triggers pain 4 to 6 cm proximal to the wrist joint dorsally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6\">",
"       6",
"      </a>",
"      ]. This maneuver may be accompanied by palpable or audible crepitus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Symptoms usually respond to rest, a neutral wrist brace with thumb spica extension, and antiinflammatory agents, with or without glucocorticoid injection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"       5",
"      </a>",
"      ]. Surgical decompression may be necessary in refractory cases. Sports activity can be gradually resumed once symptoms have resolved.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Distal radius physeal stress reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive loading of the extended wrist can lead to stress and eventual osteolysis of the distal radial growth plate. The typical patient is female, 12 to 14 years of age, and doing gymnastics about 35 hours per week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. Distal radius physeal stress reaction also occurs in rock climbers and weight lifters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4\">",
"     4",
"    </a>",
"    ]. It should be suspected in patients with dorsal pain made worse by stress loading, such as vaulting or hand-walking and no history of acute trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distal radius stress reaction may result in growth inhibition or premature growth arrest of the radius. If this occurs, there is relative overgrowth of the ulna (\"positive ulnar variance\"). Radial shortening may be accompanied by ulnocarpal impaction and tears of the TFCC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Ulnar impaction'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of acute wrist injuries in children and adolescents\", section on 'TFCC injuries'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early in the course, before radiographic changes, wrist pain with extension and axial loading may be the only manifestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. At this stage, restriction of activity for at least two to four weeks facilitates the return of full strength and pain-free range of motion. Full strength and pain-free range of motion are necessary before progressive return to grip and tumbling exercises.",
"   </p>",
"   <p>",
"    Radiographic findings, which include widening and irregularity (cystic and sclerotic changes) of the growth plate and palmar spurring of the metaphysis, indicate more severe disease. Elite gymnasts may develop radiographic changes without symptoms; regular radiographic examination may be justified in such athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once radiographic changes are present, cast or forearm-based volar splint immobilization for four to eight weeks is typically necessary for resolution of symptoms and signs. Radiographic healing lags behind clinical improvement. Restriction of activity is essential in patients with radial shortening; such patients also may require surgical treatment for ulnocarpal impingement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is a positive ulnar variance and conservative management does not improve symptoms, surgical debridement and ulnar shortening may be indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Kienb&ouml;ck's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kienb&ouml;ck's disease is a progressive collapse of the lunate (",
"    <a class=\"graphic graphic_figure graphicRef82436 \" href=\"mobipreview.htm?34/52/35651\">",
"     figure 2",
"    </a>",
"    ). The mechanism remains unclear but appears to involve disruption of the blood supply, possibly related to undiagnosed fractures of the lunate, repetitive trauma, or abnormal biomechanical loading patterns at the radiocarpal joint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kienb&ouml;ck's disease may be seen in adolescents involved in repetitive impact activities (eg, volleyball, the martial arts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/1,4,12,13\">",
"     1,4,12,13",
"    </a>",
"    ]. It affects the dominant wrist and presents insidiously; symptoms typically begin in young adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/8\">",
"     8",
"    </a>",
"    ]. The most common symptoms are dorsal wrist pain with mild swelling followed by persistent pain, crepitation, stiffness, and decreased range of motion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. There may be associated weakness or difficulty grasping heavy objects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is made radiographically (AP views). In the earliest stages, radiographs are normal but bone scan shows increased uptake and MRI shows decreased signal in the lunate on T1 images. With progression, there is increased density in the lunate (Stage 2), followed by bony collapse (Stage 3), and, finally, carpal instability and arthritis (Stage 4).",
"   </p>",
"   <p>",
"    Early referral to a hand surgeon is essential. Treatment options range from immobilization for Stage 1 disease, to revascularization, radial shortening procedures, and arthrodesis for end-stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic DRUJ and TFCC injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic DRUJ injuries are usually related to repetitive pronation as may occur in tennis, gymnastics, or bowling. Chronic DRUJ instability also may follow trauma to the wrist, presenting months later with progressive pain with supination and pronation. Initial radiographs may be normal or demonstrate degenerative changes at the sigmoid notch between the radius and ulna. Definitive treatment is usually surgical.",
"   </p>",
"   <p>",
"    Chronic TFCC injury is caused by repetitive activity involving twisting, compression, and ulnar deviation (eg, tennis, squash, ice hockey, golf, baseball, softball, boxing, water skiing, and pole vaulting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,14,16-18\">",
"     4,14,16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic TFCC tears are believed to be the result of ulnar impaction. Impaction on the lunate on the ulnar head puts increased axial pressure on the TFCC, eventually wearing it down and creating a central perforation. If impaction continues, lunate and ulnar chondromalacia develop, followed by arthritic changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Ulnar impaction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Treatment of chronic TFCC tears requires arthroscopy with repair or debridement. If ulnar impaction is the cause of the TFCC tear, an ulnar shortening procedure (to correct the underlying cause of impaction) is usually carried out in addition to TFCC debridement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuropathy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carpal tunnel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tunnel syndrome (median neuropathy) is the most common compressive neuropathy in sports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/20\">",
"     20",
"    </a>",
"    ]. It occurs in players of racquet, stick, and club sports; golfers; skiers; and cyclists and is related to the repetitive motion of grasping or extended periods of extension or flexion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carpal tunnel syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23911?source=see_link\">",
"     \"Etiology of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=see_link\">",
"     \"Clinical manifestations and diagnosis of carpal tunnel syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=see_link\">",
"     \"Treatment of carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ulnar neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compression of the ulnar nerve in Guyon's canal may occur in cyclists (related to prolonged hyperextension), hockey goaltenders, and in players of racquet sports (related to repetitive gripping and the impact of the racquet handle) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,12,21-23\">",
"     4,12,21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ulnar neuropathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of upper extremity peripheral nerve syndromes\", section on 'Ulnar nerve syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radial neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial neuropathy (Wartenberg syndrome), compression of the superficial radial nerve at the wrist, occurs in players of sports that involve repeated supination and pronation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/24\">",
"     24",
"    </a>",
"    ]. It also may occur after direct trauma.",
"   </p>",
"   <p>",
"    Patients with radial neuropathy complain of pain shooting up the thumb and paresthesias and pain over the dorsal thumb and dorsal radial hand [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/24\">",
"     24",
"    </a>",
"    ]. Radial neuropathy is treated conservatively with rest, antiinflammatory medications, and splinting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Impaction syndromes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dorsal impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsal impaction syndrome, also known as dorsiflexion jam syndrome, is an overuse syndrome that may occur in gymnasts and football offensive lineman. Clinical features include wrist swelling and pain. Radial-sided pain may be related to impaction of the distal radius on the scaphoid and lunate, whereas ulnar-sided pain may represent the ulnar impaction on the TFCC, lunate, or triquetrum. Radiographs are normal.",
"   </p>",
"   <p>",
"    Treatment involves restriction of wrist extension with extension-limiting braces and limiting stress across the injured wrist. Glucocorticoid injection also may be helpful. If there is a positive ulnar variance and conservative management does not improve symptoms, surgical debridement and ulnar shortening may be indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Scaphoid impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scaphoid impaction syndrome, a subset of dorsal impaction syndrome, is related to repetitive wrist extension, particularly with axial loading, which forces the dorsal rim of the scaphoid against the radius [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. It occurs in gymnasts (floor exercises, vaulting, balance beam), weight lifters (when resting the bar in the palms), or from excessive pushups.",
"   </p>",
"   <p>",
"    Clinical features include pain over the scapholunate ligament when the wrist is extended and axially loaded (",
"    <a class=\"graphic graphic_figure graphicRef63301 \" href=\"mobipreview.htm?38/7/39030\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6\">",
"     6",
"    </a>",
"    ]. Radiographs may be normal or demonstrate ossicle formation at the rim of the radius or dorsal scaphoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. Initial management entails avoidance of extension activities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the use of an orthoses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ulnar impaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulnar impaction syndrome, also known as ulnar abutment syndrome and ulnar impingement syndrome, results from overload of the ulnar aspect of the wrist (eg, from activities requiring ulnar deviation and pronation or abnormal positive ulnar variance) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Ulnar overload is particularly common with the vaulting in gymnastics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical findings include tenderness of the ulnar snuff box, tenderness with passive ulnar deviation, and tenderness with palmar and dorsal manipulation with the wrist in ulnar deviation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ]. Radiographic features include positive ulnar variance, or cyst formation or sclerosis of the ulnar head or lunotriquetral interface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial management includes avoidance of the precipitating activity, antiinflammatory agents,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glucocorticoid injection of the DRUJ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hypothenar hammer syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothenar hammer syndrome occurs when repetitive impact to the palmar aspect of the wrist and hand causes damage to the ulnar artery and superficial palmar arch, resulting in diminished blood flow to the fingers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Hypothenar hammer syndrome may occur in the dominant hand of players of racquet, stick, and club sports; volleyball players; and practitioners of the martial arts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. It also may occur with acute trauma.",
"   </p>",
"   <p>",
"    Clinical features include complaints of pain in the palm that may radiate to the forearm and coldness of the digits, and an abnormal modified Allen test (",
"    <a class=\"graphic graphic_figure graphicRef70306 \" href=\"mobipreview.htm?3/61/4049\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ganglion cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic irritation of the wrist causes an overproduction of joint fluid. Because of the limited capacity of the synovial cavity of the radiocarpal joint, excess synovial fluid escapes through a sinus into the subcutaneous tissues where the body confines it by forming a surrounding thick wall (a ganglion cyst). A ganglion cyst may present as an obvious swelling on physical examination, or it may only be manifested by wrist pain. The majority of wrist ganglia are located on the dorsal surface. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=see_link\">",
"     \"Ganglia and nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     NONTRAUMATIC CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wrist and hand are frequently involved in juvenile idiopathic arthritis (JIA). Chronic bilateral wrist pain and swelling may be the initial presentation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rickets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickets is the most common metabolic cause of non-traumatic wrist swelling in children. Risk factors include malabsorption, lack of sunlight exposure, malnutrition, kidney disease, and hereditary enzyme deficiencies. Laboratory findings include decreased calcium and increased phosphorus, alkaline phosphorus, and parathyroid hormone. Radiographs reveal widening of the epiphysis and fraying of the distal metaphysis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80989 \" href=\"mobipreview.htm?40/15/41206\">",
"     image 1",
"    </a>",
"    ). Early treatment is associated with improved potential for catch-up growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=see_link\">",
"     \"Overview of rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Carpal tarsal osteolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carpal tarsal osteolysis is a rare condition in which the carpal and tarsal bones are progressively resorbed. It usually presents in childhood with progressive pain and stiffness of the wrists, feet, and elbows. The clinical picture is often mistaken for JIA but labs are normal and radiographs show a characteristic appearance of the lack of any carpal bones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital wrist abnormalities include skeletal dysplasias, hereditary absent radius syndrome, constriction ring syndromes (amniotic band syndromes), and Madelung deformity. If these abnormalities are severe, they can lead to abnormal joint surface contact and the development of arthritis over time. Early swelling, due to venous or lymphatic obstruction, may occur with severe constriction ring syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36902?source=see_link\">",
"     \"Amniotic band sequence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Madelung deformity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Madelung deformity is a focal dysplasia of the distal radial physis. Premature closure leads to a progressive deformity with dorsal displacement of the ulna and palmar displacement of the carpus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Madelung deformity occurs in girls and is usually bilateral.",
"   </p>",
"   <p>",
"    Madelung deformity is usually detected between 8 and 12 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/28\">",
"     28",
"    </a>",
"    ]. Clinical features include prominence of the distal end of the ulna, limitation of supination, and DRUJ incongruity with forearm rotation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/28\">",
"     28",
"    </a>",
"    ]. Activity-related wrist pain typically develops in late adolescence. Associated conditions include Leri-Weill dyschondrosteosis, Hurler syndrome, Turner syndrome, achondroplasia, and Ollier disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of Madelung deformity is made radiographically; radiographs of both wrists, forearms, and elbows should be obtained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/28\">",
"     28",
"    </a>",
"    ]. Radiographic abnormalities include shortening of the radius and abnormal distal radial articulations. MRI or CT show physeal narrowing or closure of the palmar and ulnar aspects of the distal radial physis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38855/abstract/28\">",
"     28",
"    </a>",
"    ]. Generalized bone dysplasia and post-infectious and post-traumatic deformity should be excluded.",
"   </p>",
"   <p>",
"    The treatment depends upon severity. Early cases can be treated with serial casting or prophylactic excision of the physeal bar bridging the growth plate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overuse injuries of the wrist (",
"      <a class=\"graphic graphic_table graphicRef63434 \" href=\"mobipreview.htm?40/36/41549\">",
"       table 1",
"      </a>",
"      ) are more common among adolescents than younger children. Risk factors for overuse injuries include rapid intensification of training, muscle-tendon imbalance, poor conditioning before training, deficient nutrition, associated chronic disease, and periods of rapid growth. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overuse injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical features of tendonitis include pain that is exacerbated by activity and can be reproduced by passive stretching of the affected tendon or active contraction of the associated muscle. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tendon injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distal radius physeal stress reaction primarily occurs with repetitive loading of the extended wrist (gymnasts, rock climbers, weight lifters). It should be suspected in patients with dorsal pain made worse by stress loading. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Distal radius physeal stress reaction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Kienb&ouml;ck's disease is a progressive collapse of the lunate (",
"      <a class=\"graphic graphic_figure graphicRef82436 \" href=\"mobipreview.htm?34/52/35651\">",
"       figure 2",
"      </a>",
"      ). Clinical features include dorsal wrist pain with mild swelling followed by persistent pain, crepitation, stiffness, and decreased range of motion. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Kienb&ouml;ck's disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic distal radioulnar joint (DRUJ) and triangular fibrocartilage complex (TFCC) injuries are related to repetitive twisting of the wrist. Clinical features include progressive pain with supination and pronation. Magnetic resonance imaging may be necessary for diagnosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic DRUJ and TFCC injuries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontraumatic causes of chronic wrist pain in children and adolescents include juvenile idiopathic arthritis, rickets, and congenital deformities. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Nontraumatic causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/1\">",
"      Gill TJ 4th, Micheli LJ. The immature athlete. Common injuries and overuse syndromes of the elbow and wrist. Clin Sports Med 1996; 15:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/2\">",
"      O'Neill DB, Micheli LJ. Overuse injuries in the young athlete. Clin Sports Med 1988; 7:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/3\">",
"      Mastey RD, Weiss AP, Akelman E. Primary care of hand and wrist athletic injuries. Clin Sports Med 1997; 16:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/4\">",
"      Werner SL, Plancher KD. Biomechanics of wrist injuries in sports. Clin Sports Med 1998; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/5\">",
"      Rettig AC. Athletic injuries of the wrist and hand: part II: overuse injuries of the wrist and traumatic injuries to the hand. Am J Sports Med 2004; 32:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/6\">",
"      Nguyen DT, McCue FC 3rd, Urch SE. Evaluation of the injured wrist on the field and in the office. Clin Sports Med 1998; 17:421.",
"     </a>",
"    </li>",
"    <li>",
"     Garcia-Moral CA, Green NE, Fox JA.. Hand and wrist. In: Care of the Young Athlete, Sullivan JA, Anderson SJ.  (Eds), American Academy of Orthopedic Surgeons and American Academy of Pediatrics, 2000. p.349.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/8\">",
"      Parmelee-Peters K, Eathorne SW. The wrist: common injuries and management. Prim Care 2005; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/9\">",
"      Rettig AC. Wrist and hand overuse syndromes. Clin Sports Med 2001; 20:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/10\">",
"      Gabel GT. Gymnastic wrist injuries. Clin Sports Med 1998; 17:611.",
"     </a>",
"    </li>",
"    <li>",
"     Kramer RC, Lichtman DM. Kienbock's disease. In: The Wrist, Lippincott Williams &amp; Wilkins, Philadelphia 2001. p.395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/12\">",
"      Howse C. Wrist injuries in sport. Sports Med 1994; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/13\">",
"      Simmons BP, Lovallo JL. Hand and wrist injuries in children. Clin Sports Med 1988; 7:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/14\">",
"      Rettig AC. Athletic injuries of the wrist and hand. Part I: traumatic injuries of the wrist. Am J Sports Med 2003; 31:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/15\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/16\">",
"      Linscheid RL, Dobyns JH. Athletic injuries of the wrist. Clin Orthop Relat Res 1985; :141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/17\">",
"      Dell PC. Traumatic disorders of the distal radioulnar joint. Clin Sports Med 1992; 11:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/18\">",
"      Palmer AK, Werner FW. The triangular fibrocartilage complex of the wrist--anatomy and function. J Hand Surg Am 1981; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/19\">",
"      Cober SR, Trumble TE. Arthroscopic repair of triangular fibrocartilage complex injuries. Orthop Clin North Am 2001; 32:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/20\">",
"      Wood MB, Dobyns JH. Sports-related extraarticular wrist syndromes. Clin Orthop Relat Res 1986; :93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/21\">",
"      Frontera WR. Cyclist's palsy: clinical and electrodiagnostic findings. Br J Sports Med 1983; 17:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/22\">",
"      Osterman AL, Moskow L, Low DW. Soft-tissue injuries of the hand and wrist in racquet sports. Clin Sports Med 1988; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/23\">",
"      Plancher KD, Peterson RK, Steichen JB. Compressive neuropathies and tendinopathies in the athletic elbow and wrist. Clin Sports Med 1996; 15:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/24\">",
"      Nuber GW, Assenmacher J, Bowen MK. Neurovascular problems in the forearm, wrist, and hand. Clin Sports Med 1998; 17:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/25\">",
"      Rettig AC, Patel DV. Epidemiology of elbow, forearm, and wrist injuries in the athlete. Clin Sports Med 1995; 14:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38855/abstract/26\">",
"      Le TB, Hentz VR. Hand and wrist injuries in young athletes. Hand Clin 2000; 16:597.",
"     </a>",
"    </li>",
"    <li>",
"     Rao SB, Crawford AH. Traumatic and acquired wrist disorders in children. In: The Wrist and Its Disorders, Lichtman A.  (Ed), WB Saunders, St. Louis 1999.",
"    </li>",
"    <li>",
"     Tachdijan MO. The neck and upper limb. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.263.",
"    </li>",
"    <li>",
"     Waters PM. The upper limb. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissy RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.921.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6517 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-FD66CD12EC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38855=[""].join("\n");
var outline_f37_60_38855=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERUSE INJURIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Tendon injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Distal radius physeal stress reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Kienb&ouml;ck's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic DRUJ and TFCC injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carpal tunnel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ulnar neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radial neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Impaction syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dorsal impaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Scaphoid impaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ulnar impaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hypothenar hammer syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ganglion cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      NONTRAUMATIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rickets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Carpal tarsal osteolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Madelung deformity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6517\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6517|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?40/15/41206\" title=\"diagnostic image 1\">",
"      Rickets wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6517|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/31/1527\" title=\"figure 1\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/52/35651\" title=\"figure 2\">",
"      Kienbock disease stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/7/39030\" title=\"figure 3\">",
"      Wrist ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/61/4049\" title=\"figure 4\">",
"      Modified Allen test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6517|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/36/41549\" title=\"table 1\">",
"      Causes of chronic wrist injury in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36902?source=related_link\">",
"      Amniotic band sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/15/42230?source=related_link\">",
"      Clinical manifestations and diagnosis of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/22/23911?source=related_link\">",
"      Etiology of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32440?source=related_link\">",
"      Evaluation of wrist pain and injury in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/16/41223?source=related_link\">",
"      Ganglia and nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/8/32905?source=related_link\">",
"      Overview of acute wrist injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/21/26967?source=related_link\">",
"      Overview of rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/44/8906?source=related_link\">",
"      Overview of upper extremity peripheral nerve syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44008?source=related_link\">",
"      Treatment of carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/40/27270?source=related_link\">",
"      de Quervain's tenosynovitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38856="Iron overload syndromes other than hereditary hemochromatosis";
var content_f37_60_38856=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iron overload syndromes other than hereditary hemochromatosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38856/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/60/38856/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects there is no mechanism to regulate iron loss from the body, which averages about 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in adult men from sweat, shed skin cells, and gastrointestinal losses. Premenopausal adult women lose an additional 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    because of menses. Therefore, to insure normal stores of iron within the body, iron absorption must be tightly regulated. A simple calculation will make this clear. If iron absorption is increased in an individual by as little as 1.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    above the amount needed to achieve homeostasis, this will result in the accumulation of 5.5 grams of iron every decade, 16 grams in 30 years and 33 grams in 60 years. This latter figure corresponds to the amount of iron (30 to 40 g) usually found in patients with clinically detected hereditary hemochromatosis (HH) and explains both the delayed time for the clinical appearance of this disease in men and its rarity in premenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of the inability to increase iron loss, iron overload is an inevitable response to increased iron entry into the body. This can occur by one of three mechanisms (",
"    <a class=\"graphic graphic_table graphicRef75551 \" href=\"mobipreview.htm?41/32/42507\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A massive increase in iron intake",
"     </li>",
"     <li>",
"      An increase in iron absorption when iron intake is normal",
"     </li>",
"     <li>",
"      The parenteral administration of iron, as with transfusional overload",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will focus on the basic characteristics of the iron overload syndromes other than mutations of the iron absorption and release pathway leading to the various forms of hereditary hemochromatosis (HH). It will also include the approaches to diagnosis and therapy that are specific to each of these disorders. Four general issues are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical manifestations of iron overload (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Recommended regimen for iron removal by phlebotomy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=see_link\">",
"       \"Treatment of hereditary hemochromatosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pathophysiology/diagnosis",
"      </span>",
"      of iron overload (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Iron chelation therapy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANEMIA DUE TO INEFFECTIVE ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperplastic erythroid marrows absorb increased amounts of iron to the point where they may have clinical iron overload. Examples include the hereditary sideroblastic anemias, severe alpha and beta thalassemia, and myelodysplastic syndrome (MDS) variants such as refractory anemia with ringed sideroblasts (RARS).",
"   </p>",
"   <p>",
"    There appears to be a direct correlation between the extent of erythropoiesis and increased iron absorption. However, for unclear reasons, the enhancement in iron absorption is much more pronounced with ineffective erythropoiesis (eg, thalassemia, MDS) than with increased effective erythropoiesis (eg, hereditary spherocytosis, sickle cell anemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35750?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathophysiology of the sideroblastic anemias\", section on 'Iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=see_link&amp;anchor=H23#H23\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Congenital dyserythropoietic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism(s) underlying increased iron absorption in subjects with ineffective erythropoiesis are poorly understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/2\">",
"     2",
"    </a>",
"    ]. Some patients with idiopathic sideroblastic anemia and iron overload were found to be heterozygous for the abnormal HFE gene seen in classical hereditary hemochromatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/3\">",
"     3",
"    </a>",
"    ], while in an animal model of thalassemia and in vitro studies in man, decreases in hepcidin activity resulting in increased ferroportin activity, and thus increased iron absorption, appear to be operative [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients such as those with severe forms of beta thalassemia, the continued increased absorption of iron in the face of markedly increased iron stores has been difficult to understand. The likely explanation is based on our emerging understanding of the actions of the iron regulatory peptide hepcidin, which responds to signals of anemia and increased erythropoiesis by decreased production, and to signals of increased iron stores by increased production. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Growth Differentiation Factor 15 (GDF15) level in serum is correlated with the extent of overall erythroid maturation and is increased approximately 100-fold in patients with severe thalassemia and suppresses hepcidin mRNA expression in hepatocyte culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, in patients with increased ineffective erythropoiesis, the erythropoietic signal suppressing hepcidin synthesis overwhelms the iron stores signal, which would otherwise lead to increased hepcidin synthesis and reduced iron absorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient will have chronic anemia due to ineffective erythropoiesis in the context of hereditary or acquired sideroblastic anemia. Unless screening blood tests are performed, the presence of iron overload may not be suspected until the patient develops one of the clinical manifestations of iron overload such as skin hyperpigmentation, liver disease, diabetes mellitus, or dilated cardiomyopathy.",
"   </p>",
"   <p>",
"    Transferrin saturation is not useful in evaluating the severity of iron overload in patients with ineffective erythropoiesis. The rapid recycling of iron into and out of the marrow caused by enhanced erythropoiesis associated with extensive erythroid precursor death in the marrow often results in a transferrin saturation above 60 percent (the usual threshold for iron overload in men) even in the absence of iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/6\">",
"     6",
"    </a>",
"    ]. Measurement of the serum concentration of ferritin (the storage protein for iron) is more informative, frequently showing markedly elevated values of 2000 to 4000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (normal 40 to 200",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"   </p>",
"   <p>",
"    Liver biopsy has been, and for the immediate future may continue to be, the definitive test to establish the presence of an iron overloaded state. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are several non-invasive MRI methods now available for assessing iron stores in both liver and heart. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'CT, MRI, and SQUID techniques'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has organ involvement, as would occur in HH, and the hemoglobin concentration is 10 to 12",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    careful phlebotomy accompanied by the administration of recombinant erythropoietin (approximately 40,000 units SQ once per week) can be used to force mobilization of iron and to maintain the hemoglobin concentration. Such use of recombinant erythropoietin may not be reimbursed by the patient&rsquo;s insurance carrier.",
"   </p>",
"   <p>",
"    If the hemoglobin concentration falls to a level that produces anemic symptoms, the frequency of phlebotomy should be reduced. If this approach is not successful it may be necessary to switch to iron chelation therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Transfusional iron overload'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PORPHYRIA CUTANEA TARDA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Porphyria cutanea tarda (PCT) is primarily a skin and liver disease that occurs in familial and sporadic forms. The underlying defect in both forms is a decrease in activity of uroporphyrinogen decarboxylase (UROD) in the liver. The familial variant is also associated with a 50 percent reduction in UROD activity in red cells (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"mobipreview.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic PCT is associated with hepatitis C virus infection in 8 to 20 percent of cases in Germany and France, 30 to 60 percent in the United States, and 60 to 80 percent in Italy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=see_link&amp;anchor=H5#H5\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\", section on 'Relationship to hepatitis C virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver siderosis in sporadic PCT is responsible for inactivation of the otherwise normal UROD enzyme. The cause of the liver siderosis, as well as the cause for increased iron absorption, in sporadic PCT has not been clearly established. To some degree, HCV, a cytopathic virus, may decompartmentalize iron from within the hepatocyte, leading to the release of \"free\" iron. Consistent with this hypothesis is the observation that phlebotomy in patients with chronic hepatitis C infection and iron overload (with or without PCT) may produce significant reductions in serum aminotransferase concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxidative damage may also result in downregulation of hepcidin production, with resulting hepatic siderosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HFE gene mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There also appears to be an important contribution from mutations in the HFE gene that is responsible for hereditary hemochromatosis (HH) via an increase in intestinal iron absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link\">",
"     \"Genetics of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, HFE mutations were detected in 73 percent of patients in one series that included 26 North American patients with sporadic PCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/7\">",
"     7",
"    </a>",
"    ]. The following mutations were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C282Y &mdash; 42 percent (15 percent of whom were homozygous)",
"     </li>",
"     <li>",
"      H63D &mdash; 31 percent (8 percent of whom were homozygous)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings have been noted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In one report of 41 British patients with sporadic PCT, an HFE mutation was present in 44 percent (versus 11 percent in the general population) and 17 percent were homozygotes (versus 0.5 percent in the general population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/10\">",
"     10",
"    </a>",
"    ]. Most of these patients did not have clinical signs of HH even though they were at an age (48 to 79) when clinical HH might reasonably have appeared. In an Italian study, the H63D mutation was present in 29 percent of alleles in patients with PCT compared with 12 to 13 percent in controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of interaction between the HFE mutation and HCV infection was illustrated in a series of 108 patients with PCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared with normal controls, the patients had a marked increase in the incidence of homozygous C282Y (19 versus 0.5 percent), compound heterozygotes for HH (7 versus less than 1 percent), and HCV (59 versus 2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The implication of these findings is that patients with sporadic PCT should be tested for HCV and screened for iron status and HH, using genomic probes for HFE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients who have iron overload",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HH should be treated with phlebotomy and their families should be screened for the disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12535?source=see_link\">",
"     \"Screening for hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of HCV in patients with PCT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LIVER IRON OVERLOAD WITH NORMAL TRANSFERRIN SATURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A characteristic clinical finding in patients with HH, even when iron stores have been reduced, is an elevated transferrin saturation. The transferrin saturation is considered elevated when it is &ge;60 percent in men and &ge;50 percent in women, although some authorities consider an elevation of &gt;45 percent to be significant in men or women. However, iron overload with a normal transferrin saturation has been described in patients with insulin resistance (see below). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A common differential in HH and this disorder is alcoholic liver disease, a condition in which cirrhosis may be associated with increased serum ferritin concentrations and Perls' Prussian blue staining on liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/13\">",
"     13",
"    </a>",
"    ]. However, liver iron levels are normal or only slightly increased and body iron stores, as estimated from the response to phlebotomy, are not as markedly increased as in HH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Distinction from alcoholic liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another condition associated with iron overload, increased serum ferritin levels, and normal (or low) transferrin saturation is hereditary iron overload due to a ferroportin mutation. This condition is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High serum ferritin concentrations and normal transferrin saturation are also found in the hereditary",
"    <span class=\"nowrap\">",
"     hyperferritinemia/cataract",
"    </span>",
"    syndrome, although this condition is not associated with iron overload. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link&amp;anchor=H19#H19\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Hyperferritinemia without iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     AFRICAN IRON OVERLOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iron overload in patients with African iron overload was initially thought to result from ingestion of enormous amounts of dietary iron in the form of a traditional beer fermented in steel drums [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/14\">",
"     14",
"    </a>",
"    ]. This beer has an iron content of 80",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    and beer drinkers commonly consume several liters on weekends. Thus, iron intake in such subjects is markedly greater than the 10 to 20 mg per day in the normal Western diet.",
"   </p>",
"   <p>",
"    However, iron overload occurs in only a small number of these beer drinkers, suggesting that a genetic factor might be superimposed on an environmental factor. This theory was tested in a study of 36 such subjects, 28 of whom had increased hepatic iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/14\">",
"     14",
"    </a>",
"    ]. Iron was present in both parenchymal and reticuloendothelial cells, in contrast to its general limitation to parenchymal cells in HH. Four had a suggestive history of hepatomegaly and four came from a population screening that had both elevated serum ferritin concentrations and transferrin saturation levels above 60 percent. Genetic analyses of these subjects and relatives revealed that there is a genetic locus that leads to increased transferrin saturation in heterozygotes with higher levels in homozygotes.",
"   </p>",
"   <p>",
"    A model of the interaction between this putative gene and iron intake suggests that a 40-year-old male heterozygote with a beer consumption of 10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    would have a transferrin saturation of 75 percent and a serum ferritin level of 985",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    compared with a saturation of 36 percent and a serum ferritin of 233",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in an unaffected subject with the same beer intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several lines of evidence indicate that this putative locus is not related to the HFE gene and is not linked to HLA. In addition, polymerase chain reaction analysis of DNA from 25 southern Africans identified by segregation analysis as having a high probability of carrying the African iron loading gene failed to identify any subjects with the C282Y HFE gene mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/16\">",
"     16",
"    </a>",
"    ]. A polymorphism involving the ferroportin 1 gene has been suggested as a contributing factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics of hereditary hemochromatosis\", section on 'Ferroportin mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    African iron overload may predispose to cirrhosis, and splenic iron overloading may be associated with death from tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. As in HH, high grade iron overloading may lead to hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk of hepatocellular carcinoma in subjects with African iron overload is estimated at 3.1 times that of subjects without iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/19\">",
"     19",
"    </a>",
"    ]. This disorder has also been associated with diabetes mellitus, peritonitis, osteoporosis, malnutrition, and scurvy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=see_link\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No therapeutic studies are available in patients with African iron overload. Nevertheless, it makes sense to control the intake of iron-containing beer and to use serial phlebotomy to reduce liver and splenic iron content in patients who become iron overloaded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TRANSFUSIONAL IRON OVERLOAD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload is inevitable in patients requiring life-long transfusion support. Each unit of transfused red cells introduces 200 to 250 mg of elemental iron into the body. Since iron cannot be actively excreted, and is utilized poorly in patients with ineffective erythropoiesis, the excess iron is deposited in macrophages of the reticuloendothelial system. When this iron burden overwhelms the ability of reticuloendothelial cells to sequester the iron, parenchymal iron overload develops, leading to end-organ dysfunction, especially in the liver, myocardium, and endocrine organs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations of hereditary hemochromatosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic transfusion therapy is the cornerstone of management of children with beta thalassemia major [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, the typical thalassemic child receiving a hypertransfusion regimen has an intake of 8 to 16 mg of elemental iron per day, in contrast to 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    typical of normal subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Even though hematopoiesis is partially suppressed by hypertransfusion, accelerated oral iron absorption also contributes to the total iron overload.",
"   </p>",
"   <p>",
"    Aggressive attempts to remove iron from the body pharmacologically are necessary. Clearly, phlebotomy, the most efficacious way to remove iron in other patient groups (eg, hereditary hemochromatosis, porphyria cutanea tarda), is not an option in subjects requiring transfusion. Instead, an iron chelating agent is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic transfusional support is also employed in patients with sickle cell anemia, refractory aplastic anemia, myelodysplastic syndrome, and various leukemic states [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/27\">",
"     27",
"    </a>",
"    ]. Such patients may receive as many as 100 units of red cells, which contain up to 20 to 25 g of iron, similar to, or more than, the amount retained in many symptomatic patients with hereditary hemochromatosis. They eventually develop marked elevations in transferrin saturation and serum ferritin concentration, which may reach 2000 to 4000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (normal: 40 to 200",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    and some may develop clinical signs of iron overload (eg, liver dysfunction, heart failure, skin pigmentation, diabetes mellitus, and other endocrinopathies) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=see_link&amp;anchor=H21#H21\">",
"     \"Hepatic manifestations of sickle cell disease\", section on 'Excessive iron stores'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H2104230#H2104230\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H48#H48\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Phlebotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If patients with transfusional iron overload achieve remission and no longer require transfusion (eg, acute leukemia in prolonged complete remission, beta thalassemia major or sickle cell disease following successful hematopoietic cell transplantation), phlebotomy treatment is the safest and most efficient method to remove the excessive iron burden [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/36/43591?source=see_link&amp;anchor=H3#H3\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\", section on 'Phlebotomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=see_link\">",
"     \"Treatment of hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For subjects still requiring transfusion, iron chelation is the only available treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12918958\">",
"    <span class=\"h1\">",
"     REPEATED PARENTERAL IRON INFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload has been described in some patients on long-term hemodialysis who have received multiple infusions of intravenous iron along with erythropoietin. In one study of 115 such patients, 21 had serum ferritin levels &gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and 19 had increased levels of malonyldialdehyde, a product of lipid peroxidation, indicating oxidative stress likely due to iron toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/31\">",
"     31",
"    </a>",
"    ]. Moderate to severe iron overload was detected in the liver and spleen on MRI in 19 of 21 subjects, but iron overload was not found in the heart. This observation supports the utility of serial monitoring of ferritin levels in long-term hemodialysis patients, and suspending iron infusions when the ferritin level approaches 1000",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Iron toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=see_link&amp;anchor=H21#H21\">",
"     \"Use of iron preparations in hemodialysis patients\", section on 'Adverse effects other than anaphylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEONATAL OR PERINATAL IRON OVERLOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The literature refers to a usually fatal form of hepatic siderosis that occurs in utero or in the immediate neonatal period, previously known as neonatal or perinatal hemochromatosis, but increasingly known as &ldquo;gestational alloimmune liver disease&rdquo; because an alloimmune mechanism has been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Liver biopsy shows parenchymal iron loading with increased quantitative liver iron levels. The mother in one case was hyperferremic, but there is no relationship to HH. Some inborn errors of metabolism are also associated with hepatic iron deposition, but are caused by entirely different mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=see_link&amp;anchor=H23#H23\">",
"     \"Causes of neonatal cholestasis\", section on 'Gestational alloimmune liver disease (neonatal hemochromatosis)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INSULIN RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between otherwise unexplained hepatic iron overload and the insulin resistance syndrome has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Insulin resistance is associated with a number of clinical features including hypertension, obesity, dyslipidemia, and diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .) It has been hypothesized that insulin may have a role in hepatic iron overload by stimulating cellular iron uptake through increased transferrin receptor externalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of insulin resistance with iron overload was illustrated in a study involving 161 patients with unexplained hepatic iron overload who underwent clinical and serologic testing for evidence of insulin resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/37\">",
"     37",
"    </a>",
"    ]. The median transferrin saturation was 42 percent and the median hepatic iron concentration was 90",
"    <span class=\"nowrap\">",
"     micromol/g",
"    </span>",
"    (hepatic iron index 1.8",
"    <span class=\"nowrap\">",
"     micromol/g",
"    </span>",
"    per year). The insulin resistance syndrome was defined by the presence of a body mass index &gt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and abnormal glucose metabolism or hyperlipidemia (total fasting plasma cholesterol &gt;240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    serum triglycerides &gt;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    or hypolipidemic treatment).",
"   </p>",
"   <p>",
"    The majority of patients (94 percent) had the insulin resistance syndrome defined by these criteria. Hepatic steatosis was present in 25 percent, nonalcoholic steatohepatitis in 27 percent, and portal fibrosis in 62 percent. Patients without HFE mutations had a similar degree of iron overload as those with other genotypes, with the exception of compound heterozygotes, who had a relatively higher iron burden. The authors suggested that the diagnosis of insulin resistance hepatic iron overload can be made in patients with one or more components of the insulin resistance syndrome in association with hepatic iron load in the absence of genetic hemochromatosis. They also suggested that in addition to weight loss and other general measures, such patients should be treated with phlebotomy to remove excess iron.",
"   </p>",
"   <p>",
"    A problem with the above study was the definition of the insulin resistance syndrome, for which a consensus has not been achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/40\">",
"     40",
"    </a>",
"    ]. More than one-half of adults in the United States have a body mass index &gt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and would thus fulfill this component of the definition used in the above study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/41\">",
"     41",
"    </a>",
"    ]. As a result, more refined criteria for defining the obesity component of the insulin resistance syndrome have been proposed. In particular, the greatest risk for hepatic steatosis and the insulin resistance syndrome has been observed in patients who have central or upper body obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38856/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, other features of the insulin resistance syndrome (such as the typical pattern of dyslipidemia and the presence of hypertension) were not included in the definition. Thus, much more needs to be understood regarding the relationship of insulin resistance to hepatic iron overload and steatohepatitis, the diagnostic criteria by which the association should be identified, and its relationship to other causes of hepatic iron overload. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16073?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18047392\">",
"    <span class=\"h1\">",
"     EXTREMELY HIGH FERRITIN LEVELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extremely high ferritin levels in the absence of genetic or transfusional iron overload may be found in a number of conditions, such as juvenile idiopathic arthritis, systemic lupus erythematosus, and hemophagocytic lymphohistiocytosis (HLH). It is important that HLH be considered in this context, as this condition can be fatal if not diagnosed and treated in an urgent manner. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H14968470#H14968470\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'High levels of ferritin in the absence of iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link&amp;anchor=H24#H24\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Ferritin levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHELATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebotomy cannot be used to remove iron in transfusion-dependent subjects (eg, beta thalassemia major, sickle cell anemia, myelodysplastic syndrome), or in the rare patient with congestive failure and an unstable hemodynamic status (eg, hemochromatosis with severe cardiac involvement). Thus, if treatment for the patient's iron overload is deemed necessary, one must use an iron chelator. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10861555\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal, nonbleeding subjects there is no mechanism to regulate iron",
"    <strong>",
"     loss",
"    </strong>",
"    from the body. As a result, iron overload is an inevitable response to increased iron entry into the body. This can occur by one of three mechanisms (",
"    <a class=\"graphic graphic_table graphicRef75551 \" href=\"mobipreview.htm?41/32/42507\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A massive increase in iron intake from the diet or use of iron-containing medications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'African iron overload'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12918958\">",
"       'Repeated parenteral iron infusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increase in iron absorption when iron intake is normal (eg, ineffective erythropoiesis, hereditary hemochromatosis, liver disease, porphyria cutanea tarda, insulin resistance). These conditions are described in the text. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repeated blood transfusion. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Transfusional iron overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Treatment",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the patient is not transfusion-dependent, excess iron can be removed via phlebotomy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hereditary hemochromatosis\", section on 'Phlebotomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the patient is transfusion-dependent, or cannot receive phlebotomy treatment, iron chelation can be employed to remove excess iron from the body. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=see_link\">",
"       \"Chelation therapy for iron overload states\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/1\">",
"      Pootrakul P, Kitcharoen K, Yansukon P, et al. The effect of erythroid hyperplasia on iron balance. Blood 1988; 71:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/2\">",
"      Ginzburg Y, Rivella S. &beta;-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011; 118:4321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/3\">",
"      Barron R, Grace ND, Sherwood G, Powell LW. Iron overload complicating sideroblastic anemia--is the gene for hemochromatosis responsible? Gastroenterology 1989; 96:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/4\">",
"      Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007; 109:5027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/5\">",
"      Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/6\">",
"      Finch CA, Huebers H. Perspectives in iron metabolism. N Engl J Med 1982; 306:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/7\">",
"      Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998; 27:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/8\">",
"      Girelli CM, Mirata C, Casiraghi A. Effect of blood letting on serum aminotransferase levels of patients with chronic hepatitis C and iron overload. Recenti Prog Med 1998; 89:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/9\">",
"      Ajioka RS, Phillips JD, Weiss RB, et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008; 112:4723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/10\">",
"      Roberts AG, Whatley SD, Morgan RR, et al. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 1997; 349:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/11\">",
"      Sampietro M, Piperno A, Lupica L, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 1998; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/12\">",
"      Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000; 95:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/13\">",
"      Chapman RW, Morgan MY, Laulicht M, et al. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci 1982; 27:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/14\">",
"      Gordeuk V, Mukiibi J, Hasstedt SJ, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med 1992; 326:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/15\">",
"      Moyo VM, Mandishona E, Hasstedt SJ, et al. Evidence of genetic transmission in African iron overload. Blood 1998; 91:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/16\">",
"      McNamara L, MacPhail AP, Gordeuk VR, et al. Is there a link between African iron overload and the described mutations of the hereditary haemochromatosis gene? Br J Haematol 1998; 102:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/17\">",
"      Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol Dis 2003; 31:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/18\">",
"      Gordeuk VR, McLaren CE, MacPhail AP, et al. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996; 87:3470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/19\">",
"      Moyo VM, Makunike R, Gangaidzo IT, et al. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 1998; 60:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/20\">",
"      Walker AR, Segal I. Iron overload in Sub-Saharan Africa: to what extent is it a public health problem? Br J Nutr 1999; 81:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/21\">",
"      Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739.",
"     </a>",
"    </li>",
"    <li>",
"     Forget BG, Pearson HA. Hemoglobin synthesis and the thalassemias. In: Basic Principles and Practice, 3rd ed, Hoffma  R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.1525.",
"    </li>",
"    <li>",
"     Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Smith's Blood Diseases of Infancy and Childhood, 6th ed, Miller DR, Baehner RL (Eds), CV Mosby, St. Louis 1989. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/24\">",
"      Beris P. Introduction: management of thalassemia. Semin Hematol 1995; 32:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/25\">",
"      Cao A, Galanello R, Rosatelli MC, et al. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996; 33:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/26\">",
"      Roberts DJ, Rees D, Howard J, et al. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Syst Rev 2005; :CD004450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/27\">",
"      Parkkila S, Niemel&auml; O, Savolainen ER, Koistinen P. HFE mutations do not account for transfusional iron overload in patients with acute myeloid leukemia. Transfusion 2001; 41:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/28\">",
"      Vichinsky E, Butensky E, Fung E, et al. Comparison of organ dysfunction in transfused patients with SCD or beta thalassemia. Am J Hematol 2005; 80:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/29\">",
"      Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/30\">",
"      Franchini M, Gandini G, Veneri D, et al. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion 2004; 44:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/31\">",
"      Ghoti H, Rachmilewitz EA, Simon-Lopez R, et al. Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012; 89:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/32\">",
"      Silver MM, Beverley DW, Valberg LS, et al. Perinatal hemochromatosis. Clinical, morphologic, and quantitative iron studies. Am J Pathol 1987; 128:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/33\">",
"      Flynn DM, Mohan N, McKiernan P, et al. Progress in treatment and outcome for children with neonatal haemochromatosis. Arch Dis Child Fetal Neonatal Ed 2003; 88:F124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/34\">",
"      Pan X, Kelly S, Melin-Aldana H, et al. Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. Hepatology 2010; 51:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/35\">",
"      Moirand R, Mortaji AM, Lor&eacute;al O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/36\">",
"      Tuomainen TP, Nyyss&ouml;nen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997; 20:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/37\">",
"      Mendler MH, Turlin B, Moirand R, et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/38\">",
"      Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261:8708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/39\">",
"      Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987; 262:8975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/40\">",
"      Macdonald GA, Powell LW. More clues to the relationship between hepatic iron and steatosis: An association with insulin resistance? Gastroenterology 1999; 117:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/41\">",
"      Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998; 22:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38856/abstract/42\">",
"      Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993; 42:548.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7162 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38856=[""].join("\n");
var outline_f37_60_38856=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10861555\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANEMIA DUE TO INEFFECTIVE ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PORPHYRIA CUTANEA TARDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HFE gene mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HCV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LIVER IRON OVERLOAD WITH NORMAL TRANSFERRIN SATURATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AFRICAN IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TRANSFUSIONAL IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Phlebotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12918958\">",
"      REPEATED PARENTERAL IRON INFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEONATAL OR PERINATAL IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INSULIN RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18047392\">",
"      EXTREMELY HIGH FERRITIN LEVELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHELATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10861555\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7162\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7162|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7162|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/32/42507\" title=\"table 1\">",
"      Iron overload syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/13/2266?source=related_link\">",
"      Genetics of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2842?source=related_link\">",
"      Hepatic manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16073?source=related_link\">",
"      Pathogenesis of nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/58/35750?source=related_link\">",
"      Pathophysiology of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/15/12535?source=related_link\">",
"      Screening for hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/32/18952?source=related_link\">",
"      Treatment of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38521?source=related_link\">",
"      Use of iron preparations in hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38857="Clinical uses of amiodarone";
var content_f37_60_38857=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical uses of amiodarone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Rod Passman, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38857/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/60/38857/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27142111\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is a benzofuran that was synthesized and tested as an antianginal agent in the 1960s, but was later discovered to have antiarrhythmic properties. Amiodarone is the most widely prescribed antiarrhythmic medication in the United States, largely due to its efficacy in the management of both supraventricular and ventricular arrhythmias. In addition to the superior efficacy compared to most other antiarrhythmic drugs, amiodarone has very little negative inotropic activity, and a low rate of ventricular proarrhythmia, making it advantageous for use in patients with heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite these advantages, the use of amiodarone is associated with a relatively high incidence of side effects, making it a complicated drug to use safely.",
"   </p>",
"   <p>",
"    This topic will review the electrophysiologic properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , clinical indications, and dosing recommendations for oral and intravenous amiodarone. The side effects of amiodarone are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=see_link\">",
"     \"Amiodarone and thyroid dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27142119\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is markedly lipophilic, resulting in a very large volume of distribution (average about 66",
"    <span class=\"nowrap\">",
"     L/kg)",
"    </span>",
"    and a prolonged time to reach stable plasma levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ]. It is incompletely absorbed (approximately 30 to 70 percent) after oral administration and is taken up very extensively by tissue, with marked interindividual variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/2\">",
"     2",
"    </a>",
"    ]. Estimates of the elimination half-life of amiodarone vary, depending on how the half-life has been measured and the route of amiodarone administration. The relatively short half-life for disappearance of amiodarone from plasma after a single-dose or short-term intravenous administration is likely a measure of drug redistribution from vascular space into tissue and not true body elimination. After long-term oral therapy, amiodarone has a true elimination half-life between 60 and 142 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Slow and wide distribution to tissue (fat, muscle, highly perfused organs) results in a requirement of long loading periods in an effort to accelerate the onset of drug activity. However, even with loading, arrhythmia recurrence during the first months of therapy does not necessarily predict long-term efficacy. Conversely, intravenous (IV) amiodarone begins to act within one hour, with rapid onset of action within minutes following an IV bolus.",
"   </p>",
"   <p>",
"    There is little correlation between the plasma concentration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or its major active metabolite, desethylamiodarone, and drug efficacy or toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is a potent inhibitor of CYP3A4, which can lead to significant drug interactions. (See",
"    <a class=\"local\" href=\"#H4967572\">",
"     'Drug interactions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27142126\">",
"    <span class=\"h1\">",
"     ELECTROPHYSIOLOGIC PROPERTIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrophysiologic properties of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are complex and incompletely understood. Though classified as a Vaughan-Williams class III antiarrhythmic agent due to its inhibition of outward potassium channels, the drug also has class I sodium channel blocking effects, class II antiadrenergic effects, and class IV calcium channel blocking effects (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"mobipreview.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ). The oral and intravenous forms of amiodarone have important electrophysiologic differences that have an impact on their clinical use (",
"    <a class=\"graphic graphic_table graphicRef79689 \" href=\"mobipreview.htm?39/53/40796\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27142133\">",
"    <span class=\"h2\">",
"     Oral amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is classified as a class III antiarrhythmic agent, since it prolongs the duration of the action potential and the refractory period of both atrial and ventricular tissue (",
"    <a class=\"graphic graphic_figure graphicRef64133 \" href=\"mobipreview.htm?26/24/27023\">",
"     figure 1",
"    </a>",
"    ). This effect is primarily mediated by blockade of the inward potassium channel rectifier (IKr), the rapid component of the cardiac delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like other class III agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/32/13829?source=see_link\">",
"     ibutilide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/3/5176?source=see_link\">",
"     dronedarone",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    prolongs the QT interval. However, in contrast to most other class III agents, amiodarone has very little proarrhythmic activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link&amp;anchor=H6#H6\">",
"     \"Major side effects of amiodarone\", section on 'Cardiac toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has several other effects that may contribute to its therapeutic efficacy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It inhibits inactivated (phase 0) sodium channels, an effect that is primarily seen at rapid heart rates",
"     </li>",
"     <li>",
"      It has some class II antiarrhythmic drug activity, inhibiting sympathetic activity, primarily by causing noncompetitive beta receptor blockade",
"     </li>",
"     <li>",
"      It also has some class IV antiarrhythmic drug activity by blocking L-type (slow) calcium channels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004678\">",
"    <span class=\"h2\">",
"     Intravenous amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has a number of important electrophysiologic differences from chronic oral amiodarone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It produces a much smaller increase in the action potential duration in atrial and ventricular myocardium, and a minimal increase in the atrial and ventricular refractory periods. As a result, there is little or no increase in QRS duration or the QT interval, respectively.",
"     </li>",
"     <li>",
"      It has little effect on sinus cycle length. It has vasodilator activity that triggers an increase in sympathetic activity, and as a result, there is little or no slowing of the sinus rate.",
"     </li>",
"     <li>",
"      It may have more potent and more rapid antiadrenergic activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Like oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , IV amiodarone inhibits inactivated sodium channels, though to a lesser degree than the oral form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/4\">",
"     4",
"    </a>",
"    ]. This property may account for the efficacy of the agent in the suppression of ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/6\">",
"     6",
"    </a>",
"    ]. IV amiodarone also prolongs atrioventricular (AV) nodal conduction and refractoriness, and may be effective in slowing the ventricular rate in critically ill patients with atrial tachyarrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004686\">",
"    <span class=\"h2\">",
"     Effects on the ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multiple actions of chronic oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    therapy can produce a variety of changes in the electrocardiogram. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slowing of the sinus rate, even at therapeutic drug levels. Both calcium channel blockade and beta blockade may contribute to this effect, which can lead to sinus bradycardia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolongation of the PR interval and the atrioventricular (AV) nodal refractory period. Thus, AV conduction block may occur, an effect that may also be related to calcium channel blockade since the AV node is a \"slow response\" tissue that relies on an inward calcium current for depolarization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link&amp;anchor=H6#H6\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\", section on 'Action potential in slow response tissues'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Widening of the QRS complex, as conduction is slowed in ventricular muscle by the blocking effect on the inactivated sodium channel, thereby slowing phase 0 depolarization (",
"      <a class=\"graphic graphic_figure graphicRef64133 \" href=\"mobipreview.htm?26/24/27023\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolongation of the QT interval due to blockade of IKr, the delayed rectifier potassium current that is responsible for phase 3 depolarization of the action potential (",
"      <a class=\"graphic graphic_figure graphicRef64133 \" href=\"mobipreview.htm?26/24/27023\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link&amp;anchor=H6#H6\">",
"       \"Major side effects of amiodarone\", section on 'Cardiac toxicity'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004209\">",
"    <span class=\"h1\">",
"     ORAL AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    can be used to treat most types of atrial arrhythmias but is used primarily to maintain normal sinus rhythm in patients with atrial fibrillation (AF). However, oral amiodarone is not FDA approved in the United States for rhythm control in AF, despite common usage for this indication. It is commonly used for several reasons including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      is the most effective medical therapy available for maintaining sinus rhythm",
"     </li>",
"     <li>",
"      There is a low risk of ventricular proarrhythmia based on the electrophysiologic properties of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      does not increase mortality in heart failure patients",
"     </li>",
"     <li>",
"      Therapy can be easily initiated on an outpatient basis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, if AF recurs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    usually slows the ventricular response at rest and with exercise. It also may reduce symptoms associated with rapid ventricular response to AF, though amiodarone is not recommended solely as a rate controlling agent (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=see_link&amp;anchor=H12#H12\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Amiodarone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    can be used to treat other atrial arrhythmias such as atrial flutter or atrial tachycardia, but the availability of other antiarrhythmic drugs with lower toxicity rates and the high success rates of ablative approaches to these arrhythmias often favors these alternatives. The major limiting factor in the use of oral amiodarone for the treatment of AF and other atrial arrhythmias is toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17047167\">",
"    <span class=\"h2\">",
"     Oral amiodarone to prevent recurrent paroxysmal atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to pursue a strategy of rhythm control in any patient with atrial fibrillation (AF) is complex and depends on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence or absence of symptoms",
"     </li>",
"     <li>",
"      Potential adverse effects of persistent AF (ie, uncontrolled ventricular rate)",
"     </li>",
"     <li>",
"      Adverse effects of alternative therapies for AF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of which antiarrhythmic drug to use is also complex and based on a variety of factors, most notably the presence and type of structural heart disease. Unlike many other antiarrhythmic drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    has a low risk of ventricular proarrhythmia and does not increase mortality when administered to patients with coronary disease, left ventricular hypertrophy, left ventricular dysfunction, or congestive heart failure. While there is no universally accepted dosing regimen, oral loading doses of 600 to 800 mg per day in divided doses for outpatients and 1.2 to 1.8 grams per day in divided doses in inpatients (up to a total loading dose of 10 grams) are often used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/9\">",
"     9",
"    </a>",
"    ]. Gastrointestinal side effects may limit loading doses. The usual maintenance dose for AF is 200 mg daily. Doses up to 400 mg per day may also be used but are not recommended for routine maintenance given the higher risk of adverse events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17047227\">",
"    <span class=\"h2\">",
"     Oral amiodarone for pharmacologic cardioversion of atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    can result in pharmacologic cardioversion of atrial fibrillation in up to 40 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of the potential for cardioversion following administration of amiodarone, standard precautions need to be considered to prevent thromboembolic events. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is not a first-line therapy for pharmacologic cardioversion given its limited efficacy and long onset of action. If amiodarone is used in this setting,",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    Guidelines recommend oral loading and maintenance doses the same as those described above for amiodarone use to maintain sinus rhythm in patients with paroxysmal AF. Amiodarone and other pharmacologic agents for cardioversion are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701755#H8701755\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Antiarrhythmic drugs used in cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17047234\">",
"    <span class=\"h2\">",
"     Oral amiodarone prior to elective cardioversion for persistent atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who did not remain in sinus rhythm following electrical cardioversion, or in patients deemed high risk for recurrent atrial fibrillation (AF) after planned cardioversion, pretreatment with antiarrhythmic agents including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is often prescribed. Given the prolonged half-life of oral amiodarone, the drug should be started two to six weeks prior to elective cardioversion to reduce the risk of recurrence. Dosing regimens vary but generally aim for an oral load of 6 to 10 grams over a period of two to six weeks prior to cardioversion, with a decrease in dose to maintenance levels following cardioversion or shortly thereafter. Given the unique pharmacologic properties of amiodarone, AF recurrences in the first two to three months following cardioversion do not necessarily predict long-term failure of the drug. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H8701669#H8701669\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Pretreatment with antiarrhythmic drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17047241\">",
"    <span class=\"h2\">",
"     Oral amiodarone for prophylaxis against atrial fibrillation following cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    lowers the incidence of postoperative atrial fibrillation (AF) in patients undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/9\">",
"     9",
"    </a>",
"    ]. Various dosing regimens for oral amiodarone have been used in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. These trials are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H17#H17\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Amiodarone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004252\">",
"    <span class=\"h1\">",
"     INTRAVENOUS AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is primarily used for the treatment of atrial arrhythmias in three settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restoration and maintenance of sinus rhythm in critically ill patients with hemodynamically unstable atrial fibrillation (AF)",
"     </li>",
"     <li>",
"      Rate control in critically ill patients with AF with rapid ventricular response in whom the tachycardia is contributing to hemodynamic compromise",
"     </li>",
"     <li>",
"      Prevention of AF following cardiac surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    requires attention to a specific dosing schedule to minimize side effects, which are largely different from those seen with chronic oral therapy. In addition, there is substantial interindividual variability in response time; as a result, careful patient observation and dose adjustment are recommended as necessary.",
"   </p>",
"   <p>",
"    An initial IV loading dose of 150 mg is given over a minimum of 10 minutes. More rapid infusion increases the risk of hypotension. The loading dose should be followed by a continuous infusion of 1",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    for six hours and 0.5",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ]. This regimen delivers 1050 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in the first 24 hours. Patients who develop hypotension, which occurs in as many as 26 percent of cases, may benefit from a decrease in the infusion rate, while additional IV boluses may be beneficial in patients with recurrent arrhythmias during the early phase of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Amiodarone should be mixed in a 5 percent dextrose solution and the amiodarone concentration kept below 2",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    if given through a peripheral vein to minimize the development of local phlebitis. Higher drug concentrations must be delivered through an indwelling catheter in a central vein.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is physically incompatible with a number of drugs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , which should not be given in the same solution. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link&amp;anchor=H2#H2\">",
"     \"Major side effects of amiodarone\", section on 'Intravenous amiodarone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004275\">",
"    <span class=\"h2\">",
"     IV amiodarone to restore and maintain sinus rhythm in critically ill patients with hemodynamically unstable atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is common in critically ill patients and may contribute to hemodynamic instability. Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    can be used in this situation but has not been sufficiently studied in this population to allow for specific recommendations. In general, the reported efficacy of IV amiodarone in restoring and maintaining sinus rhythm is inconsistent, though",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    Guidelines list intravenous amiodarone as a Class IIa indication for pharmacological cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several meta-analyses have been published evaluating the efficacy of IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in restoration of normal sinus rhythm in critically-ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The meta-analyses have included studies with widely varying methodologies, leading to some conflicting results. The largest meta-analysis included studies comparing amiodarone to other antiarrhythmic drugs or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/14\">",
"     14",
"    </a>",
"    ]. IV amiodarone was as efficacious as other antiarrhythmic drugs and more effective than placebo, but amiodarone was associated with a higher rate of adverse events compared to placebo. Another meta-analysis which included only studies comparing amiodarone to placebo or class Ic antiarrhythmic drugs determined that conversion from AF to sinus rhythm was greater 8 and 24 hours, but not at one or two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=see_link&amp;anchor=H952132725#H952132725\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Candidates for cardioversion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversion rates from AF to sinus rhythm following IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    are higher when the bolus (3 to 7",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    is followed by continuous infusion (900 to 3000 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004289\">",
"    <span class=\"h2\">",
"     IV amiodarone to control the ventricular response in critically ill patients with atrial fibrillation and rapid ventricular response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) with rapid ventricular response may contribute to hemodynamic compromise. Furthermore, ventricular rates greater than &gt;120",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    for prolonged periods of time may contribute to left ventricular dysfunction. Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be used as a rate controlling agent in critically ill individuals with hemodynamically destabilizing AF who cannot be maintained in sinus rhythm and in whom standard rate-controlling therapies have been either unsuccessful or are contraindicated due to hypotension. In a retrospective study, ICU patients with hemodynamically destabilizing AF or atrial flutter resistant to conventional therapy experienced a significant 37",
"    <span class=\"nowrap\">",
"     beat/minute",
"    </span>",
"    decrease in ventricular rate and an increase in systolic blood pressure of 24 mm Hg with no associated adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    may be also be used for rate control in patients with congestive heart failure and those with accessory pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard dose in all of these settings is 150 mg over 10 minutes with a maintenance dose of 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/minute.",
"    </span>",
"    Repeated 150 mg boluses can be given over 10 to 30 minutes. Hypotension is more likely at daily doses above 2000 mg. As a result, no more than six to eight additional boluses may be possible in any 24-hour period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17047353\">",
"    <span class=\"h2\">",
"     IV amiodarone for prophylaxis against atrial fibrillation following cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    appears to have some efficacy in preventing postoperative atrial fibrillation (AF) in patients undergoing coronary artery bypass graft (CABG) surgery. However, in patients undergoing cardiac valvular surgery where the risks of postoperative AF is greater, and the degree of left atrial enlargement and atrial remodeling more extensive, the benefit of prophylactic intravenous (IV) amiodarone for the prevention of post-operative AF is less certain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The efficacy of postoperative IV therapy was documented in the ARCH trial in which 300 patients were randomly assigned to 1 gram of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or placebo administered intravenously over 24 hours for two days; therapy was begun immediately after CABG. Amiodarone significantly reduced the incidence of atrial fibrillation (35 versus 47 percent for placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single-center, double-blinded, randomized controlled trial in patients undergoing valvular surgery, patients received either an IV loading does of 300 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      or placebo in the operating room, followed by an infusion of 15",
"      <span class=\"nowrap\">",
"       mg/kg/24",
"      </span>",
"      hr for two days. The primary endpoint was the development of atrial fibrillation occurring at any time within the postoperative period. One hundred twenty patients were randomly assigned (mean age was 65 &plusmn; 11 year). Overall, atrial fibrillation occurred more frequently in the perioperative intravenous amiodarone group compared with the placebo group (59.3 versus 40.0 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    following cardiac surgery depends on the type of cardiac surgery. Additional studies are needed to assess the efficacy of amiodarone in prevention of post-operative atrial fibrillation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004619\">",
"    <span class=\"h1\">",
"     CLINICAL USES OF AMIODARONE FOR VENTRICULAR ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004627\">",
"    <span class=\"h2\">",
"     Oral amiodarone for the treatment of ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    suppresses ventricular premature depolarizations (VPDs) and episodes of nonsustained ventricular tachycardia (VT). This is clearly demonstrated in several of the primary prevention trials of amiodarone in postmyocardial infarction and congestive heart failure patients in whom baseline and follow-up 24-hour ambulatory ECGs were performed. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Canadian",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      Myocardial Infarction Arrhythmia Trial (CAMIAT) pilot study enrolled patients with frequent or repetitive asymptomatic VPDs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/18\">",
"       18",
"      </a>",
"      ]. When compared to placebo, patients receiving amiodarone had much greater suppression of VPDs and nonsustained VT (86 percent compared with 50 percent of placebo patients).",
"     </li>",
"     <li>",
"      The CHF-STAT trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      versus placebo in patients with heart failure, left ventricular ejection fraction of 40 percent or less, and frequent ventricular premature beats (more than 10 per hour) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/19\">",
"       19",
"      </a>",
"      ]. Following two weeks of treatment, significantly fewer patients on amiodarone had ventricular tachycardia on Holter monitor (33 versus 76 percent). Despite the reduction in ventricular arrhythmias and ectopy, amiodarone did not reduce mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional trials are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=see_link&amp;anchor=H31035829#H31035829\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\", section on 'Amiodarone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is also one of the few antiarrhythmic drugs that does not increase mortality when given to patients with moderate to severe left ventricular dysfunction. The apparent efficacy and safety of amiodarone for the treatment of ventricular tachyarrhythmias in patients with structural heart disease has lead to several studies evaluating the impact of amiodarone on survival in patients at high risk of arrhythmic death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004642\">",
"    <span class=\"h2\">",
"     Oral amiodarone for the primary prevention of sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias are responsible for a large proportion of sudden cardiac deaths, especially in those individuals with underlying structural heart disease. The ability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    to suppress ventricular arrhythmias led to several trials designed to assess its effect on patients deemed high risk for ventricular arrhythmias either because they have already survived a sustained ventricular tachyarrhythmia or were believed to be at high risk of developing such arrhythmias due to the presence of left ventricular dysfunction.",
"   </p>",
"   <p>",
"    Earlier studies comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    with standard medical therapy generally enrolled patients with either recent MI or congestive heart failure. A meta-analysis of these trials based on individual patient data yielded a relative risk reduction in all-cause mortality of 13 to 15 percent with amiodarone, which was of borderline statistical significance depending on the analytical method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/2\">",
"     2",
"    </a>",
"    ]. In subsequent trials, amiodarone was compared with implantable cardioverter-defibrillator (ICD) therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. These trials demonstrated the superiority of ICD therapy compared to amiodarone in the primary prevention of sudden cardiac death. As a result, amiodarone use is considered reasonable only for patients who are candidates for an ICD and have left ventricular dysfunction due to prior myocardial infarction, but who cannot or refuse to have an ICD implanted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommended loading dose for the prevention of ventricular arrhythmias is 400 to 1200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (usually in divided doses) for a total of 8 to 10 grams [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ]. Higher loading-dose regimens have been evaluated but do not appear to provide greater efficacy. Maintenance doses range from 200 to 400 mg per day with the lower doses carrying less risk of adverse side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004670\">",
"    <span class=\"h2\">",
"     Oral amiodarone for the secondary prevention of sudden cardiac death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survivors of sudden cardiac death (SCD) due to arrhythmia carry a high risk of recurrence. With the possible exception of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , attempts to significantly reduce SCD rates by using antiarrhythmic drugs have yielded disappointing results, most likely related to the proarrhythmic effects of many antiarrhythmic drugs. The recognition of the limitations of antiarrhythmic drugs for secondary prevention was paralleled by the development of smaller, transvenous implantable cardioverter-defibrillators (ICDs) with tiered therapies, bradycardia pacing, and success rates of &gt;95 percent in terminating ventricular tachycardia (VT) and ventricular fibrillation (VF).",
"   </p>",
"   <p>",
"    Several randomized trials and meta-analyses have compared ICDs to antiarrhythmic drugs for secondary prevention of SCD in patients with resuscitated VF, sustained VT with syncope, or sustained VT with ejection fraction &le;40 percent, and evidence of hemodynamic compromise. All show superior efficacy of ICD compared with antiarrhythmic drugs. In view of the superiority of ICD compared to antiarrhythmics for the secondary prevention of SCD,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    should not be used as for secondary prevention except in those who do not meet implant criteria, or who meet criteria, but cannot receive a device or refuse device implantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dosing regimen for this indication is similar to that in primary prevention. (See",
"    <a class=\"local\" href=\"#H6004642\">",
"     'Oral amiodarone for the primary prevention of sudden cardiac death'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H907869\">",
"    <span class=\"h2\">",
"     Oral amiodarone for the prevention of ventricular arrhythmias in patients with ICDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shocks delivered by an implantable cardioverter-defibrillator (ICD), especially when repetitive, can be painful and impact quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    may be used to decrease the risk of ICD shocks.",
"   </p>",
"   <p>",
"    The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Study evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    plus beta blocker,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    alone, and beta blocker alone for the prevention of ICD shocks in 412 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/24\">",
"     24",
"    </a>",
"    ]. Amiodarone plus beta blocker significantly reduced the risk of shock compared with beta blocker alone (HR 0.27, 95% CI 0.14-0.52) or sotalol alone (HR 0.43, 95% CI 0.22-0.85). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in patients with ICDs, reassessment of defibrillation threshold may be necessary in those individuals with marginally acceptable defibrillation threshold prior to drug initiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/25\">",
"     25",
"    </a>",
"    ]. Additionally, care must be taken in device programming as amiodarone may produce VT slowing such that the cycle length of spontaneous ventricular tachycardia fall below the programmed detection rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39672?source=see_link&amp;anchor=H5#H5\">",
"     \"Implantable cardioverter-defibrillators: Patient follow-up\", section on 'Defibrillation function testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H23#H23\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Increased defibrillation threshold'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H907921\">",
"    <span class=\"h2\">",
"     IV amiodarone for the treatment of electrical storm and incessant ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in the treatment of electrical storm and incessant ventricular tachycardia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/376?source=see_link\">",
"     \"Electrical storm and incessant ventricular tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H907928\">",
"    <span class=\"h2\">",
"     IV amiodarone during resuscitation from cardiac arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    as part of the advanced cardiac life support protocol for resuscitation of cardiac arrest is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004579\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4967557\">",
"    <span class=\"h2\">",
"     Transition from IV to oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bioavailability of oral compared to intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ranges from 30 to 70 percent and is increased in the presence of food. Additionally, an increase in plasma levels may not be seen for four to five hours after the ingestion of oral amiodarone. We suggest the following approach to converting IV to oral amiodarone dosing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have been on IV therapy for more than two weeks can be started on maintenance oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      at a dose of 200 to 400",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Patients who have been on IV therapy for one to two weeks can be started on an intermediate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      dose of 400 to 800",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      This should be continued until a total loading dose of 10 grams has been received, then the dose should be reduced to the usual maintenance dose of 200 to 400",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Patients who have been on IV therapy for one week or less should probably receive the usual oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      loading dose of 400 to 1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (typically in two divided doses). This should be continued until a total loading dose of 10 grams has been received, then the dose should be reduced to the usual maintenance dose of 200 to 400",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Both oral and IV therapy can be given concurrently for a few days if there is a concern about gastrointestinal tract function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4967564\">",
"    <span class=\"h2\">",
"     Dose adjustment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is metabolized in the liver. The major metabolite is desethylamiodarone, which is active and has a longer elimination half-life than amiodarone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"     1",
"    </a>",
"    ]. Dose reduction is probably necessary in patients with significant hepatic disease. In comparison, there is minimal elimination of both amiodarone and desethylamiodarone by the kidneys due both to the large volume of distribution and extensive protein binding; the latter effect also minimizes drug removal by dialysis. As a result, the dose of amiodarone does not have to be reduced in patients with renal disease or in patients undergoing dialysis. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     \"Amiodarone: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4967572\">",
"    <span class=\"h2\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    is highly bound to plasma proteins (&gt;96 percent) and can alter the plasma concentration of other highly bound drugs. Interactions with other drugs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , must be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can interfere with the metabolism of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , thereby raising the plasma digoxin concentration and potentially leading to digoxin toxicity. The dose of digoxin should be empirically reduced by 50 percent at the time of amiodarone initiation or the need for digoxin reevaluated altogether. Digoxin levels should be measured within three days after amiodarone initiation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can also interfere with the metabolism of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , which often necessitates a reduction in warfarin dose to prevent an elevation in the INR and potential bleeding complications. The INR level should be checked more frequently in the one to two weeks after amiodarone is initiated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific interactions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     \"Amiodarone: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990251\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has unique characteristics that mandate cautious use in pregnancy. The complications which can occur with the use of amiodarone during pregnancy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypothyroidism or hyperthyroidism in the mother or fetus because of the iodine in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"     </li>",
"     <li>",
"      Fetal bradycardia",
"     </li>",
"     <li>",
"      Fetal QT interval prolongation",
"     </li>",
"     <li>",
"      Premature labor",
"     </li>",
"     <li>",
"      Low birth weight",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    is found in fetal tissue and breast milk. For these reasons, the use of amiodarone in pregnancy should be reserved for maternal and fetal arrhythmias not responding to agents with known safety. Concomitant beta blocker therapy should be avoided. Breast feeding is not recommended when the mother is taking amiodarone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37030?source=see_link\">",
"     \"Maternal conduction disorders and bradycardia during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonates of mothers taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    should have complete thyroid function tests and developmental follow-up. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5990258\">",
"    <span class=\"h2\">",
"     Use in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in the treatment of tachyarrhythmias in children has been reported in several small series, the overall safety and efficacy of amiodarone in children has not been fully established. Amiodarone appears to be effective in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among children with supraventricular tachycardia, IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is a second-line therapy for conversion to sinus rhythm, and oral amiodarone is a second-line therapy for the prevention of recurrent arrhythmia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15514?source=see_link\">",
"       \"Management of supraventricular tachycardia in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      has also been used, alone or in combination with other antiarrhythmic drugs, in infants and children with resistant, life-threatening ventricular tachyarrhythmias [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. Potential pacing for bradyarrhythmias may be necessary when amiodarone is given after surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Optimal dosing is less well established in children.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For oral therapy, dosing is based upon body weight or, in children less than one year of age, upon body surface area. The loading dose, which can be given in one or two divided doses per day, is 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 600 to 800",
"      <span class=\"nowrap\">",
"       mg/1.73",
"      </span>",
"      m2 per day for 4 to 14 days or until adequate control of the arrhythmia is attained or prominent adverse effects occur. The dose should then be reduced to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 200 to 400",
"      <span class=\"nowrap\">",
"       mg/1.73",
"      </span>",
"      m2 per day once daily for several weeks. If the arrhythmia does not recur, the lowest effective dose should be used for maintenance. The usual minimal dose is 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day.",
"     </li>",
"     <li>",
"      For IV therapy in critically ill children with tachyarrhythmias who have not responded to standard therapy, two dosing regimens have been reported:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A loading dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      divided into five 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      aliquots, with each aliquot given over five to 10 minutes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/26\">",
"       26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      If necessary, additional 1 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      doses can be given 30 minutes later on a similar schedule. The average loading dose is 6.3",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      Among those requiring a continuous infusion, the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      infusion rate is typically 7 to 10",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min (10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      A loading dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      infused over one hour, then a maintenance infusion rate starting at 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38857/abstract/27\">",
"       27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The mean effective maintenance dose is 9.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min (13.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     \"Amiodarone: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6004536\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    does have many potential benefits, side effects are a serious concern. Of greatest concern are potential toxicities involving the lungs, thyroid, liver, eyes, and skin. The potential side effects related to amiodarone usage are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4967607\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      , initially developed as an antianginal therapy, has various electrophysiologic properties which are favorable in the treatment of tachyarrhythmias. There are important differences in these properties between the oral and intravenous preparations. (See",
"      <a class=\"local\" href=\"#H27142126\">",
"       'Electrophysiologic properties'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      can slow the sinus heart rate, prolong the PR interval, widen the QRS complex, and prolong the QT interval on surface electrocardiogram. (See",
"      <a class=\"local\" href=\"#H6004686\">",
"       'Effects on the ECG'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is an effective antiarrhythmic drug for the maintenance of sinus rhythm in patients with AF. Amiodarone is safe for use in outpatients and in patients with heart failure. (See",
"      <a class=\"local\" href=\"#H6004209\">",
"       'Oral amiodarone for the treatment of atrial arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is effective for restoration and maintenance of sinus rhythm in critically ill patients with hemodynamically unstable AF. In addition, it can be used for rate control in critically ill patients with AF with rapid ventricular response (who failed cardioversion or are unable to be cardioverted) in whom the tachycardia is contributing to hemodynamic compromise. (See",
"      <a class=\"local\" href=\"#H6004252\">",
"       'Intravenous amiodarone for the treatment of atrial arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both oral and IV regimens of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      have been used successfully as prophylaxis against AF in patients undergoing cardiac surgery. (See",
"      <a class=\"local\" href=\"#H17047241\">",
"       'Oral amiodarone for prophylaxis against atrial fibrillation following cardiac surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17047353\">",
"       'IV amiodarone for prophylaxis against atrial fibrillation following cardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      suppresses ventricular tachycardia significantly better than placebo, has less proarrhythmic effects than other antiarrhythmic drugs, and does not appear to increase mortality in heart failure patients. (See",
"      <a class=\"local\" href=\"#H6004627\">",
"       'Oral amiodarone for the treatment of ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite its effectiveness in reducing ventricular tachycardia,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      has consistently been inferior to implantable cardioverter-defibrillators (ICDs) in reducing mortality in both primary and secondary prevention studies of patients at high risk for sudden cardiac death. Thus, the use of amiodarone in this setting should be reserved for patients who are candidates for an ICD but who cannot or refuse to have an ICD implanted. (See",
"      <a class=\"local\" href=\"#H6004642\">",
"       'Oral amiodarone for the primary prevention of sudden cardiac death'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6004670\">",
"       'Oral amiodarone for the secondary prevention of sudden cardiac death'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with an ICD who have received shocks for ventricular tachyarrhythmias report significant pain and a reduced quality of life due to fears about recurrent shocks. In this setting,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      is a highly effective adjunctive therapy to reduce the risk of further shocks. (See",
"      <a class=\"local\" href=\"#H907869\">",
"       'Oral amiodarone for the prevention of ventricular arrhythmias in patients with ICDs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The dosing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      following conversion from IV to oral administration varies according to the duration of IV treatment prior to conversion. (See",
"      <a class=\"local\" href=\"#H4967557\">",
"       'Transition from IV to oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      has the potential for numerous drug interactions and side effects that require monitoring. (See",
"      <a class=\"local\" href=\"#H4967572\">",
"       'Drug interactions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/1\">",
"      Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007; 4:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/2\">",
"      Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/3\">",
"      Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/4\">",
"      Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/5\">",
"      Gomes JA, Kang PS, Hariman RJ, et al. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J 1984; 107:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/6\">",
"      Scheinman MM, Levine JH, Cannom DS, et al. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation 1995; 92:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/7\">",
"      Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998; 81:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/8\">",
"      Kamiya K, Nishiyama A, Yasui K, et al. Short- and long-term effects of amiodarone on the two components of cardiac delayed rectifier K(+) current. Circulation 2001; 103:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/9\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Fuster V, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/10\">",
"      Daoud EG, Strickberger SA, Man KC, et al. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. N Engl J Med 1997; 337:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/11\">",
"      Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001; 357:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/12\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/13\">",
"      Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003; 89:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/14\">",
"      Hilleman DE, Spinler SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002; 22:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/15\">",
"      Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/16\">",
"      Beaulieu Y, Denault AY, Couture P, et al. Perioperative intravenous amiodarone does not reduce the burden of atrial fibrillation in patients undergoing cardiac valvular surgery. Anesthesiology 2010; 112:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/17\">",
"      Guarnieri T, Nolan S, Gottlieb SO, et al. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol 1999; 34:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/18\">",
"      Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/19\">",
"      Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/20\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/21\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/22\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/23\">",
"      Passman R, Subacius H, Ruo B, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med 2007; 167:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/24\">",
"      Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA 2006; 295:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/25\">",
"      Hohnloser SH, Dorian P, Roberts R, et al. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial. Circulation 2006; 114:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/26\">",
"      Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38857/abstract/27\">",
"      Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74:573.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 926 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38857=[""].join("\n");
var outline_f37_60_38857=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4967607\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27142111\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27142119\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27142126\">",
"      ELECTROPHYSIOLOGIC PROPERTIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27142133\">",
"      Oral amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004678\">",
"      Intravenous amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004686\">",
"      Effects on the ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6004209\">",
"      ORAL AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17047167\">",
"      Oral amiodarone to prevent recurrent paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17047227\">",
"      Oral amiodarone for pharmacologic cardioversion of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17047234\">",
"      Oral amiodarone prior to elective cardioversion for persistent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17047241\">",
"      Oral amiodarone for prophylaxis against atrial fibrillation following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6004252\">",
"      INTRAVENOUS AMIODARONE FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004275\">",
"      IV amiodarone to restore and maintain sinus rhythm in critically ill patients with hemodynamically unstable atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004289\">",
"      IV amiodarone to control the ventricular response in critically ill patients with atrial fibrillation and rapid ventricular response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17047353\">",
"      IV amiodarone for prophylaxis against atrial fibrillation following cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6004619\">",
"      CLINICAL USES OF AMIODARONE FOR VENTRICULAR ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004627\">",
"      Oral amiodarone for the treatment of ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004642\">",
"      Oral amiodarone for the primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6004670\">",
"      Oral amiodarone for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H907869\">",
"      Oral amiodarone for the prevention of ventricular arrhythmias in patients with ICDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H907921\">",
"      IV amiodarone for the treatment of electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H907928\">",
"      IV amiodarone during resuscitation from cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6004579\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4967557\">",
"      Transition from IV to oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4967564\">",
"      Dose adjustment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4967572\">",
"      Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5990251\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5990258\">",
"      Use in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6004536\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4967607\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/926\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/926|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/24/27023\" title=\"figure 1\">",
"      Action potential and ECG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/926|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/53/40796\" title=\"table 2\">",
"      Oral versus intravenous amiodarone",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25065?source=related_link\">",
"      Amiodarone and thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=related_link\">",
"      Amiodarone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/23/376?source=related_link\">",
"      Electrical storm and incessant ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/47/39672?source=related_link\">",
"      Implantable cardioverter-defibrillators: Patient follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15514?source=related_link\">",
"      Management of supraventricular tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37030?source=related_link\">",
"      Maternal conduction disorders and bradycardia during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38858="Assessment and management of depression in palliative care";
var content_f37_60_38858=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment and management of depression in palliative care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     William Breitbart, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Anna L Dickerman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Susan D Block, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/60/38858/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/60/38858/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced illness often experience psychological distress. While emotional distress is natural and expected in individuals experiencing serious illness and confronting the end of their lives, the differentiation between a normal and appropriate reaction to dying versus a more serious psychiatric disorder such as major depression can be clinically challenging.",
"   </p>",
"   <p>",
"    This topic reviews assessment and management of depression in patients receiving palliative care for serious illness. The basic principles of palliative care, assessment and management of other symptoms that are prevalent among patients with advanced illness, as well as psychosocial, existential, and spiritual issues in palliative care are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=see_link\">",
"     \"Palliative care: Benefits, services, and models of care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=see_link\">",
"     \"Overview of comprehensive patient assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=see_link\">",
"     \"Approach to symptom assessment in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=see_link\">",
"     \"Overview of managing common non-pain symptoms in palliative care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link\">",
"     \"Psychosocial issues at the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCOPE OF THE PROBLEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive syndromes are a common mental health problem in palliative medicine, yet are widely misunderstood, underdiagnosed, and undertreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Data on the prevalence of moderate to severe depression in the last six months of life for patients with terminal cancer were provided by a unique observational cohort study of all cancer decedents in Ontario Canada between 2007 and 2009 (",
"    <a class=\"graphic graphic_figure graphicRef59669 \" href=\"mobipreview.htm?34/45/35537\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians often fail to recognize the extent of a patient's depression until too late in the course of the disease. As an example, in a survey of 1046 consecutive hospice patients, only 10 percent were prescribed antidepressants at some point during hospice care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients prescribed tricyclic antidepressants were nearly always underdosed, and three-fourths of those started on antidepressants died within two weeks.",
"   </p>",
"   <p>",
"    Among the many barriers to the recognition and treatment of psychological symptoms in patients with advanced illness are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mistaken belief that all patients facing or contemplating the end of life are \"depressed\"",
"     </li>",
"     <li>",
"      The clinician's lack of knowledge and skill at recognizing and treating major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fear of upsetting the patient or intruding at an emotionally vulnerable time",
"     </li>",
"     <li>",
"      The stigma associated with psychiatric diagnoses such as major depression",
"     </li>",
"     <li>",
"      Apprehension about possible drug-drug interactions with psychotropic agents",
"     </li>",
"     <li>",
"      When caring for patients with advanced illness, clinicians themselves may feel a sense of hopelessness that can lead to therapeutic nihilism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Burden of depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological distress is a major cause of suffering among patients with advanced disease or terminal illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Depressive syndromes are highly correlated with a reduced quality of life, greater difficulty in managing the course of the patient's illness, decreased adherence to treatment, and earlier admission to inpatient or hospice care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/1,11-16\">",
"     1,11-16",
"    </a>",
"    ]. Depression also impairs the patient's capacity for pleasure, meaning, connection, and doing the emotional work of separating and saying goodbye; it amplifies pain and other symptoms, and causes anguish and worry in family members and friends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Depression, suicide, and desire for a hastened death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with advanced illness who suffer from depressive syndromes are also at high risk of suicide and suicidal ideation, and they have an increased desire for a hastened death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/4,17-23\">",
"     4,17-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study concluded that suicidal ideation was relatively infrequent in cancer, and limited to those who were significantly depressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of psychiatric consultation data from Memorial Sloan-Kettering Cancer Center, one-third of suicidal cancer patients had major depression, and 50 percent were diagnosed with an adjustment disorder with features of both anxiety and depression at the time of evaluation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/21,24\">",
"       21,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although some studies suggest that hopelessness is a significantly better predictor of completed suicide than is depression alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/25-27\">",
"       25-27",
"      </a>",
"      ], others have found that a clinical diagnosis of depression, the severity of depressive symptoms, and a sense of hopelessness are all strong and independent predictors of a desire for hastened death in the terminally ill [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/20\">",
"       20",
"      </a>",
"      ]. Depression, hopelessness, and general psychological distress are also consistently associated with interest in physician-assisted suicide and euthanasia; as many as 59 percent of patients requesting assisted suicide are depressed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=see_link&amp;anchor=H13#H13\">",
"       \"Euthanasia and physician assisted suicide\", section on 'Attitudes and practices of patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevalence of depression in palliative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of depressive syndromes in patients with advanced or terminal illness varies widely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Cancer patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of major depression in individuals with cancer varies from 3 to 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/29-35\">",
"     29-35",
"    </a>",
"    ]. This wide variability is explained by the lack of agreement as to appropriate diagnostic criteria to be used in the setting of advanced illness (",
"    <a class=\"graphic graphic_table graphicRef81607 \" href=\"mobipreview.htm?15/49/16155\">",
"     table 1",
"    </a>",
"    ), differences in patient populations (ie, demographics, type and stage of disease, treatment versus no treatment), and variation in assessment methods. In general, rates are higher in populations with advanced cancer, greater levels of disability,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unrelieved pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/32,34,36-38\">",
"     32,34,36-38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Assessment and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Even when the most stringent criteria are used, major depression is diagnosed in approximately 7 percent, and minor depression in 11 percent of patients with advanced cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/32,37-39\">",
"     32,37-39",
"    </a>",
"    ]. The reported prevalence of depression in terminally-ill cancer patients is between 13 and 26 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/12,20,40,41\">",
"     12,20,40,41",
"    </a>",
"    ]. These rates are significantly higher than one month prevalence rates of depression in the general North American population, which range from 1.6 to 4.9 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Non-cancer populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similarly, patients with other advanced medical illnesses also appear to have elevated rates of depression. Within non-cancer populations, depression has been identified in up to 27 percent of patients with end-stage renal disease and those seeking to discontinue dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], 20 to 40 percent of those with Parkinson disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], 35 percent of patients with advanced multiple sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/46\">",
"     46",
"    </a>",
"    ], and 22 to 46 percent of patients with advanced heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Depression is also a common symptom in patients with AIDS, affecting 23 to 52 percent of those with end-stage disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12504?source=see_link\">",
"     \"Depression, mania, and schizophrenia in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=see_link\">",
"     \"Palliative care: End-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An awareness of the specific risk factors for depressive disorders in patients receiving end of life care may facilitate early diagnosis and intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Age and gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several (but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/52\">",
"     52",
"    </a>",
"    ]) studies, younger cancer patients have higher rates of depressive disorders and self-reported distress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/53-57\">",
"     53-57",
"    </a>",
"    ]. While depression is twice as common in women as compared to men in the general population, gender is not consistently reported to be a risk factor for depression in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/32,58\">",
"     32,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prior history of depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A past history of depression is a risk factor for major depression in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/5,59\">",
"     5,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Uncontrolled symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of uncontrolled symptoms, particularly pain, is a major risk factor for depression and suicide among patients with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Some speculate that depression may result in an amplification of pain, while others suggest that it lessens the ability to tolerate the stress of physical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Thus, the causal pathway may be bidirectional [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Type of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of depression also depends upon the patient's particular illness. Among cancer patients, those with head and neck and pancreatic cancers are at a particularly high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/32,66\">",
"     32,66",
"    </a>",
"    ]. For patients with pancreatic cancer, psychiatric symptoms may precede the physical symptoms of the disease by several months, leading some to propose that tumor-induced changes in the neuroendocrine system may contribute to depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/60,66,67\">",
"     60,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Illness and treatment-related factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain factors associated with the patient's illness or its treatment may be associated with depression. Tumors arising within or metastasizing to the central nervous system can cause depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/15,57,68,69\">",
"     15,57,68,69",
"    </a>",
"    ]. In the case of pituitary tumors, this may be related to excess cortisol production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Metabolic complications such as hypercalcemia, often associated with breast and lung cancers, can also be associated with depression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depression is common among patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS.",
"    </span>",
"    HIV infection increases the risk of depression both through direct damage to subcortical brain areas, and by disease-related chronic stress, social isolation, and intense demoralization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5831?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the neuropsychiatric aspects of HIV infection and AIDS\", section on 'Major Depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other causes of depression in cancer patients include toxins created by a tumor, possibly autoimmune reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/73\">",
"     73",
"    </a>",
"    ], viral infections, and nutritional deficiencies. Depression can also represent an adverse effect from certain treatments, including glucocorticoids; chemotherapy drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , asparaginase, intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/74-81\">",
"     74-81",
"    </a>",
"    ]) as well as radiotherapy to the brain or head and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/82-86\">",
"     82-86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Existential concerns and spirituality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition of a life-threatening crisis brings existential concerns (unfulfilled ambitions, the meaning of life, maintaining dignity at the end of life) to the forefront [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/1\">",
"     1",
"    </a>",
"    ]. Existential suffering and deep personal anguish are some of the most distressing experiences that occur in the dying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/87\">",
"     87",
"    </a>",
"    ]. The relationship between existential distress and depressive syndromes among the terminally ill is not well studied. In one study, existential distress (ie, concerns related to loss of meaning in life) showed a higher correlation with scores on depression scales than did items pertaining to physical symptoms, medical treatment, or social isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have high levels of spiritual well-being tend to be less depressed. The inverse correlation between religious",
"    <span class=\"nowrap\">",
"     beliefs/spirituality",
"    </span>",
"    and severity of depressive symptoms was shown in a sample of 162 terminally ill patients with cancer and AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/88\">",
"     88",
"    </a>",
"    ]. The beneficial aspects of religion related primarily to spiritual well-being rather than to formal religious practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link\">",
"     \"Psychosocial issues at the end of life\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=see_link\">",
"     \"Religion, spirituality, and end of life care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASSESSMENT AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressed mood, sadness, grief, and anticipatory feelings of loss are all appropriate responses to advanced disease and dying. However, feelings of hopelessness, helplessness, worthlessness, guilt, lack of pleasure, and suicidal ideation (even mild or passive) are among the best indicators of depressive syndromes in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/21,24,89\">",
"     21,24,89",
"    </a>",
"    ]. Passive suicidal ideation (I'd be better off dead) should be distinguished from active suicidal ideation (I&rsquo;m going to kill myself). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary of some of the contrasting characteristics of normal grief versus depression in terminally-ill patients is provided in a table (",
"    <a class=\"graphic graphic_table graphicRef53062 \" href=\"mobipreview.htm?35/46/36587\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two important caveats:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Feelings of hopelessness, helplessness, and guilt must be considered in the context of the patient's illness. Hopelessness may be difficult to interpret in the setting of a disease where there is no hope for cure or recovery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/27\">",
"       27",
"      </a>",
"      ]. Furthermore, patients may feel helpless because of their physical condition, or there may be a sense of guilt if the illness is related to certain behaviors (eg, cirrhosis and hepatocellular cancer in alcoholics, lung cancer in smokers). Symptoms that seem out of proportion to the patient's actual situation should prompt concern for major depression.",
"     </li>",
"     <li>",
"      There is considerable overlap between the neurovegetative or somatic symptoms of major depression (eg, fatigue, insomnia, anorexia, and weight loss) and those associated with any serious illness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      its treatment. This has led some to exclude these symptoms from diagnostic criteria for depression in medically ill patients, a subject which is discussed in detail below. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Criterion-based diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tools for assessment and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major types of research methods that are available for the assessment of depression in advanced illness: criterion-based instruments, which may be based upon a diagnostic classification scheme or the outcome of a structured diagnostic interview, and self-report measures. The available tools are summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef66861 \" href=\"mobipreview.htm?0/63/1021\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Criterion-based diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely used criteria to diagnose depression in nonterminally ill patients are those outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/90\">",
"     90",
"    </a>",
"    ]. If sufficient criteria are not met for the diagnosis of major depression, then patients may be classified as \"adjustment disorder\" with depressive features, or mood disorder secondary to medical condition.",
"   </p>",
"   <p>",
"    Small differences between investigators in the application of symptom severity thresholds (eg, the severity with which symptoms must be expressed before they are considered clinically significant) can result in large differences in prevalence rates for depression in studied populations. Furthermore, as noted previously, because somatic complaints in medically ill patients may also be attributable to the physical effects of the illness or its treatment, their use as diagnostic criteria can also affect the rate of diagnosis of major depression in medically ill patients, particularly when they are used in conjunction with a low-threshold symptom severity approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of these issues, several general approaches to the diagnosis of major depression in the medically ill have evolved, which differ in how they deal with somatic symptoms and in the definition of symptom severity. These approaches are outlined in a table (",
"    <a class=\"graphic graphic_table graphicRef81607 \" href=\"mobipreview.htm?15/49/16155\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most widely used is the substitutive approach of Endicott [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/91\">",
"     91",
"    </a>",
"    ]. The Endicott scale replaces four of the DSM-IV-TR somatic criteria thought most likely attributable to medical illness or its treatment (ie, change of",
"    <span class=\"nowrap\">",
"     weight/appetite,",
"    </span>",
"    sleep disturbance, loss of",
"    <span class=\"nowrap\">",
"     energy/fatigue,",
"    </span>",
"    difficulty thinking or concentrating) with cognitive substitutes (depressed appearance, social withdrawal,",
"    <span class=\"nowrap\">",
"     brooding/self-pity/pessimism,",
"    </span>",
"    and lack of reactivity in situations that would normally be pleasurable) (",
"    <a class=\"graphic graphic_table graphicRef60631 \" href=\"mobipreview.htm?1/14/1260\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the substitutive approach is used most often for research purposes, most experts agree that for clinical purposes, the use of a modified inclusive set of diagnostic criteria that incorporates both neurovegetative and psychological symptoms of depression, and emphasizes the presence of hopelessness, worthlessness, guilty, and suicidal ideation is most appropriate for the palliative care population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/1,92\">",
"     1,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Self-report instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criterion-based diagnostic systems require an in-depth clinical interview. Self-report methods (eg, the 9-item Patient Health Questionnaire (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"mobipreview.htm?14/12/14541\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], 21-item Beck Depression inventory [BDI] or the shorter 13-item scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/95,96\">",
"     95,96",
"    </a>",
"    ], or visual analog scales [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]) may be used if a direct face to face interview is not feasible. However, these self-report scales are only a crude substitute for a careful diagnostic interview. The efficacy of these tools as a diagnostic aid in the palliative care setting is not as good as a brief interview directly addressing the commonly accepted diagnostic criteria. Situations where they might be useful include providing additional information in difficult cases, quantifying the severity of a depressive syndrome after initial diagnosis, or monitoring changes in depression over time.",
"   </p>",
"   <p>",
"    A self-report measure designed to differentiate between preparatory grief and depression in adults (the Terminally Ill Grief or Depression Scale, TIGDS) has been developed and validated in a small series of 47 adult inpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/99\">",
"     99",
"    </a>",
"    ]. The tool is comprised of grief and depression subscales totaling 47 questions, and is described as easy to administer and acceptable to patients. However, the TIGDS has not been tested in other clinical settings, and requires validation in larger samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Simple screening instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful diagnostic interview remains the gold standard method for assessment of depression in medically-ill patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"     8",
"    </a>",
"    ]. However, direct face-to-face interviews are time-consuming, thus limiting their usefulness in palliative-care settings.",
"   </p>",
"   <p>",
"    More than 50 questionnaires have been developed to aid the detection of depression or severe distress, but most have been validated in primary care patients. Few have been studied specifically in palliative care settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/100-102\">",
"     100-102",
"    </a>",
"    ], and most of these are too long for routine use. Assessment of depression in advanced illness requires instruments that are not only valid and reliable, but also minimally burdensome, acceptable to patients, and easy to administer and score.",
"   </p>",
"   <p>",
"    Simple one or two-question, and other abbreviated assessments appear to be as effective as longer instruments in screening for depression in most (",
"    <a class=\"graphic graphic_table graphicRef61549 \" href=\"mobipreview.htm?28/53/29531\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/95,97,103-109\">",
"     95,97,103-109",
"    </a>",
"    ] but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/110\">",
"     110",
"    </a>",
"    ]. The single-item screen is adapted from the SADS (Schedule for Affective Disorders and Schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/103\">",
"     103",
"    </a>",
"    ]) depression criteria, and consists simply of asking the question:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Have you been depressed most of the time for the past two weeks?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This method appears to be accurate for identifying patients who might qualify for a diagnosis of depression on the basis of a full interview covering all of the criterion symptoms, and thus is a useful screening tool to select patients who need further evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/95-97,100,104,105,111,112\">",
"     95-97,100,104,105,111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of this approach was shown in a study of 200 palliative care in-patients with terminal cancer that compared the performance of four brief screen measures for depression, including the single-item question \"Are you depressed?\", a two-item question assessing depressed mood and loss of interest or pleasure in activities, a visual analog scale (VAS) for mood based on the Memorial Pain Assessment Card [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/105\">",
"     105",
"    </a>",
"    ], and the Beck Depression Inventory (BDI), short version [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/97\">",
"     97",
"    </a>",
"    ]. Using a semi-structured diagnostic interview as the gold standard for diagnosis, the single-item interview (using a threshold stringency equivalent to patients feeling depressed \"most of the time\") outperformed both the BDI and the VAS. The two-item scale did not identify more depressed patients, and it characterized four patients as being depressed who were classified as not depressed after the full interview.",
"   </p>",
"   <p>",
"    The sensitivity and specificity of a single-item question as a screen for depression has been shown by others in diverse cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/100,111,112\">",
"     100,111,112",
"    </a>",
"    ], although conflicting results have been observed in palliative care populations in the United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/102,110,113\">",
"     102,110,113",
"    </a>",
"    ] and in Japan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/114\">",
"     114",
"    </a>",
"    ]. This is perhaps not surprising. While some patients may readily verbalize that they are depressed, others, no matter how despairing, may never acknowledge it, or may label it something else (eg, nervousness) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for distress management from the National Comprehensive Cancer Network (NCCN) suggest the use of a VAS (ranging from no distress to extreme distress) as well as patient self report of depression, sadness, and loss of interest in usual activities (yes or no) as a screen for depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/115\">",
"     115",
"    </a>",
"    ]. Both methods are reasonable as screening tools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depression in palliative care or terminally-ill patients is treatable. The more favorable side effect profile of newer antidepressants (eg, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors) has facilitated their use in the elderly and medically ill. Because treatment with these agents is relatively benign and well tolerated, clinicians should have a low threshold for initiating therapy. Psychostimulants, in comparison with other antidepressants, have a faster onset of activity and are the preferred initial option for palliative care patients whose life expectancy is less than two to four months or for those in need of urgent treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     General treatment principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. Although pain is most often an issue in the setting of cancer, patients who have diseases that are not usually considered painful (eg, cardiac disease) may also experience moderate to severe pain at the end of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=see_link\">",
"     \"Assessment of cancer pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All patients should have a complete medical evaluation to assess possible general medical contributors to depressed mood. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Illness and treatment-related factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If depression persists once pain is controlled, and a potentially reversible general medical cause of depressed mood cannot be identified, specific therapy is warranted. Treatment should be tailored to the individual needs of the patient. In addition to drug therapy, effective psychosocial interventions include individual or group psychotherapy, hypnotherapy, cognitive-behavioral therapy (eg, relaxation training and biofeedback), existential therapy, and self-help groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/117-121\">",
"     117-121",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link\">",
"     \"Complementary and alternative therapies for cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials that specifically address the benefit of psychotherapy for palliative care patients with depression, and few that address pharmacologic treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/122\">",
"     122",
"    </a>",
"    ]. As a result, therapy for depression in these patients is generally based upon the larger body of evidence on effective treatments in patients with cancer, or primary care populations with either no physical illness or less severe medical conditions. Although there is a lack of controlled trials to support the efficacy of combined therapy, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16601?source=see_link\">",
"     \"Depression in adults: Supportive psychotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Psychosocial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad range of psychological interventions have been found to be effective for the treatment of major depression in a variety of patients, including those with cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/123-128\">",
"     123-128",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link\">",
"     \"Overview of psychotherapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Psychotherapy increases the effectiveness of drug therapy for major depression in older primary care patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/129,130\">",
"     129,130",
"    </a>",
"    ], and most experts recommend a combined approach in medically ill patients as well, despite the lack of evidence from randomized trials to support this practice. However, patients with severe depressive symptoms may be too",
"    <span class=\"nowrap\">",
"     immobilized/or",
"    </span>",
"    and dysphoric to effectively engage in psychotherapy; such patients may first need to receive appropriate pharmacotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Supportive psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important aspect of psychotherapeutic support for depressed terminally-ill patients is the therapeutic alliance between the patient and the primary medical caregiver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. Optimally, this relationship will be one of mutual trust, respect, and sensitivity. Maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated, and reassures the patient that he or she will not be abandoned throughout the course of the terminal illness.",
"   </p>",
"   <p>",
"    Supportive psychotherapy aims to support adaptive coping mechanisms, minimize maladaptive ones, and decrease adverse psychological reactions such as fear, shame, self-loathing, and withdrawal. The main components of psychotherapy are active listening, supportive verbal interventions, and occasional interpretation.",
"   </p>",
"   <p>",
"    Clinicians should elicit from the patient his or her concerns about death and the dying process, but need not focus solely on the issue of death. Patients should be encouraged to talk about their lives and experiences, fears about the impact of illness on family members, and past experiences of coping with loss. Patients should be encouraged to freely talk about or ask questions about their prognosis, with their therapist taking an interested and interactive role in the discussion. Reassurance is useful when it is based on a specific understanding of the individual's status and is not clinically unrealistic.",
"   </p>",
"   <p>",
"    Supportive therapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker, depending on time, interest, training, and the severity of the patient's condition. Sometimes, supportive psychotherapy alone is sufficient to treat depression. Treating major depression with supportive psychotherapy is discussed in more detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16601?source=see_link\">",
"     \"Depression in adults: Supportive psychotherapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Structured cognitive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral techniques, which focus on distorted thoughts that adversely affect mood, are often integrated into depression therapy. These approaches explore patients' beliefs about the cancer diagnosis and its treatment and attempt to elicit irrational or unhelpful thoughts that lead to feelings of helplessness and hopelessness. Therapy then leads to the correction of these maladaptive thoughts along with providing new coping skills (eg, relaxation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Cognitive-behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Existential psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious illness has a profound impact on the sense of self; the physical and psychological losses that are often part of the illness challenge one's sense of wholeness and integrity, which are key components of emotional health. Serious illness also challenges personal values of independence and control (which together form the construct of dignity), as well as self-determination and self-worth.",
"   </p>",
"   <p>",
"    Existential therapies such as dignity therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/132-134\">",
"     132-134",
"    </a>",
"    ] and meaning-centered psychotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/135,136\">",
"     135,136",
"    </a>",
"    ] may represent appropriate choices for some terminally ill patients who confront daily choices that affect quality of life, and who often have questions about the meaning, purpose, and value of life. Such therapy can improve spiritual wellbeing, lessen sadness and depression, and sustain or enhance a sense of meaning, peace, and purpose at the end of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=see_link&amp;anchor=H13#H13\">",
"     \"Psychosocial issues at the end of life\", section on 'Maintaining hope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with psychotherapy, there is a general lack of high-quality evidence regarding the effectiveness of antidepressants in patients with major depression who are receiving end of life care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. There are no randomized trials focusing on this population. However, randomized trials and meta-analyses document the efficacy of antidepressants in depressed patients with physical illness, including those with &ldquo;life-threatening&rdquo; physical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/137\">",
"     137",
"    </a>",
"    ]. Furthermore, a systematic review of antidepressants for treatment of depression in palliative care, which included 25 placebo-controlled randomized trials, demonstrated significant benefit of treatment over placebo within four to five weeks, with continued improvement over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/138\">",
"     138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of psychiatric and psychologic disorders in patients with cancer\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Drug selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several classes of antidepressants, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychostimulants (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32454?source=see_link\">",
"       dextroamphetamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"       modafinil",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitors (SSRIs) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"       \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tricyclic (TCAs) and tetracyclic antidepressants (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"       \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serotonin modulators (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"       nefazodone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39175?source=see_link\">",
"       vilazodone",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Atypical antidepressants (eg, agomelatine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"       \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Monoamine oxidase inhibitors (MAOIs), which are rarely used in palliative care (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"       \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The agents used most commonly in palliative care patients are psychostimulants, SSRIs, and TCAs (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). Although there is no evidence that any particular antidepressant or class of antidepressants is preferable for patients receiving end of life or palliative care, the 2008 clinical practice guidelines for initial treatment of depression in primary care patients from the American College of Physicians make a strong recommendation to initiate an SSRI, SNRI, or atypical antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/139\">",
"     139",
"    </a>",
"    ]. The most compelling reason why SSRIs are usually selected for initial therapy in depressed primary care patients is not because of demonstrated greater efficacy, but because of their more favorable side effect profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/140,141\">",
"     140,141",
"    </a>",
"    ] and the markedly lower danger with overdose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is some evidence that TCAs might be preferred for severely depressed patients. In general, patients with severe depression are less likely to drop out of treatment trials because of unacceptable side effects when taking an SSRI as compared to a TCA, but are more likely to drop out because of treatment inefficacy. Evidence-based European guidelines for management of depression in palliative cancer care do not endorse any one category of antidepressants for initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/142\">",
"     142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of depression in adults\", section on 'Choice of antidepressant'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to these drugs, psychostimulants are an important option for treatment of depression at the end of life because, unlike classic antidepressants, they take effect quickly.",
"   </p>",
"   <p>",
"    For palliative care patients, the factors that influence the choice of initial agent in addition to side effect profile (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 8",
"    </a>",
"    ) are the available time frame for treatment, coexisting medical problems and symptoms, and pharmacologic properties (eg, half life, potential for drug-drug interactions, and availability of liquid formulation):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While patients with an anticipated life expectancy of several months can afford to wait one or two weeks for a TCA or SSRI to begin working (as long as immediate onset of action is not essential), those with a shorter remaining lifespan (or severe depression requiring urgent treatment) do better with rapidly-acting psychostimulants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/143-145\">",
"       143-145",
"      </a>",
"      ]. Psychostimulants are useful for the treatment of depressive symptoms who are weeks from death. Even patients who are extremely debilitated and fatigued may experience improvement in mood and energy within 24 to 48 hours of starting treatment (",
"      <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"       table 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Psychostimulants may also be useful as initial agents for patients with a relatively long estimated life span who have severe depression and require urgent treatment. An antidepressant such as an SSRI can then be introduced and the dose increased to therapeutic levels over one to two weeks while the dose of the psychostimulant is gradually decreased.",
"     </li>",
"     <li>",
"      Elderly patients and those with cardiovascular disease should avoid drugs that cause orthostatic hypotension (eg, TCAs, (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"       table 8",
"      </a>",
"      )). Similarly, because they lack anticholinergic effects, SSRIs are preferred for patients with slowed intestinal motility or urinary retention, as well as those who have stomatitis or chronic dry mouth secondary to chemotherapy or radiotherapy.",
"     </li>",
"     <li>",
"      For patients who are at risk for seizures or who may have a lower seizure threshold because of other medications,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/18/16678?source=see_link\">",
"       maprotiline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      should be avoided as they are associated with the highest seizure risk (",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"       table 8",
"      </a>",
"      ). However, virtually any antidepressant can have a small effect on lowering the seizure threshold, and all agents should be used cautiously in patients with central nervous system (CNS) disease.",
"     </li>",
"     <li>",
"      Side effects may sometimes be used to the patient's advantage. As an example, the depressed patient who is experiencing agitation or insomnia may benefit from the more sedating antidepressants (eg, TCAs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"       mirtazapine",
"      </a>",
"      , [(",
"      <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"       table 8",
"      </a>",
"      )]). By contrast, patients with fatigue or psychomotor slowing may do better with compounds that have the least sedating effects (eg, SSRIs and psychostimulants).",
"      <br/>",
"      <br/>",
"      In addition to their antidepressant action, the TCAs have analgesic properties (as do SNRIs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/62/37864?source=see_link\">",
"       duloxetine",
"      </a>",
"      ), and they potentiate the effects of opioid analgesics. Thus, patients who are experiencing pain, particularly neuropathic pain, may benefit from these agents alone or in combination with other drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H19#H19\">",
"       \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Antidepressants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Liquid formulations are available for some antidepressants (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"       escitalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"       nortriptyline",
"      </a>",
"      ), and may be preferred for patients who cannot swallow pills.",
"     </li>",
"     <li>",
"      Rather than continuously experimenting with a range of different drugs, clinicians should become comfortable with prescribing a single drug from each class in order to become familiar with dosing regimens, actions, interactions, and side effects. Specific interactions of antidepressants with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, SSRIs are preferred for first-line therapy. SSRIs are generally as effective as TCA's for the treatment of depression, and they have a wider margin of safety than TCAs in the event of an overdose.",
"   </p>",
"   <p>",
"    There are currently six SSRIs marketed in the United States:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). All have similar efficacy, but differ in pharmacokinetics, drug interactions, and side effect profile. Although SSRIs are generally well-tolerated, dose-related side effects, such as jitteriness, restlessness, anxiety, agitation, headache, sexual dysfunction, gastrointestinal symptoms (diarrhea and nausea), and insomnia are common, and may be problematic in debilitated patients (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 8",
"    </a>",
"    ). Headache and jitteriness often subside after the first four to seven days of antidepressant initiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    was shown to significantly improve quality of life and depressive symptoms in patients with advanced cancer in two of the only controlled trials carried out in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/146,147\">",
"     146,147",
"    </a>",
"    ]. However, the clinical use of this agent in palliative care is limited by its long half-life (it takes five to six weeks to reach steady state drug concentrations) and the potential for significant drug-drug interactions because it inhibits hepatic drug metabolizing enzymes such as cytochrome P450 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. Specific interactions of fluoxetine and other SSRIs with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions. The specific cytochrome enzymes that each SSRI and their metabolites potently or moderately inhibit are summarized elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=see_link&amp;anchor=H399780619#H399780619\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\", section on 'Drug-drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the long half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    , steady state levels are reached in 4 to 14 days with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    . However, the advantages of a shorter half-life SSRI such as paroxetine and fluvoxamine in ill cancer patients is counterbalanced by the fact that a missed dose may result in fairly rapid and unpleasant withdrawal syndrome. This does not tend to happen with sertraline.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    are also likely to be better tolerated by terminally ill patients than other SSRIs because they have fewer active metabolites which can accumulate and cause toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    have significantly fewer interactions with hepatic metabolizing enzymes than the other SSRIs, making them appealing choices in patients who are on other medications where drug-drug interactions are a concern.",
"   </p>",
"   <p>",
"    As in elderly individuals, the initial SSRI dose for patients with advanced or endstage medical illness should be approximately one-half that used in otherwise healthy patients (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Tricyclic antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have demonstrated the efficacy of TCAs in depressed, medically-ill patients, although none are controlled trials.",
"   </p>",
"   <p>",
"    Although TCAs are still used in terminally ill cancer patients, they are not as well tolerated as SSRIs because of their sedating and autonomic effects, which can be particularly troublesome for terminally-ill patients (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). The major side effects are anticholinergic effects, including dry mouth, blurred vision, constipation, urinary retention, tachycardia, orthostatic hypotension, and impaired memory, confusion or delirium (",
"    <a class=\"graphic graphic_table graphicRef62488 \" href=\"mobipreview.htm?37/46/38639\">",
"     table 8",
"    </a>",
"    ). These adverse effects can be particularly problematic for patients receiving other medications with anticholinergic properties (",
"    <a class=\"graphic graphic_table graphicRef57410 \" href=\"mobipreview.htm?41/32/42508\">",
"     table 9",
"    </a>",
"    ). Such patients are at risk for developing anticholinergic delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/150\">",
"     150",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     Desipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    are less anticholinergic than other tricyclics.",
"   </p>",
"   <p>",
"    The elderly are particularly susceptible to memory impairment, confusion, and hallucinations. Sedation is a particular problem with the tertiary amine tricyclics (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ), which can exacerbate the sedating effects of other medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older patients and those with advanced medical illness have a higher likelihood of drug intolerance and drug-drug interactions. Specific interactions of these agents with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"     \"Diagnosis and management of late-life depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If TCAs are chosen as the initial agent for older patients, they should be started at low doses and slowly titrated (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). In order to minimize drug toxicity and more carefully guide the drug titration process, TCAs with well-established therapeutic plasma levels and generally better tolerance profiles, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/21/30040?source=see_link\">",
"     nortriptyline",
"    </a>",
"    , should be prescribed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/151\">",
"     151",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=see_link\">",
"     \"Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Other antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/45/22233?source=see_link\">",
"     Venlafaxine",
"    </a>",
"    is a potent serotonin-norepinephrine reuptake inhibitor (SNRI, (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    )). Its use in terminally-ill depressed patients has not been studied, but its pharmacokinetic properties and generally well tolerated side-effect profile suggest that it is a potentially useful agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/41/32408?source=see_link\">",
"     Mirtazapine",
"    </a>",
"    has also been shown to be effective for improving multiple symptoms, depression, and quality of life in patients with advanced cancer, although it is relatively sedating [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    can be an effective antidepressant, but it is also sedating (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ). It may be given at low doses to treat depressed cancer patients with insomnia, and may also be useful for patients who require adjunct analgesic effect in addition to antidepressant effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. Trazodone has also been associated with priapism and should thus be used with caution in male patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/154\">",
"     154",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/0/2057?source=see_link\">",
"     Nefazodone",
"    </a>",
"    has been associated with liver failure, and probably should not be used in this patient population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=see_link&amp;anchor=H19#H19\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Antidepressants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/29/26073?source=see_link\">",
"     Bupropion",
"    </a>",
"    is not the first drug of choice for the treatment of depression in terminally ill patients, although it may be considered for patients who have a poor response to the trial of other antidepressants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=see_link\">",
"     \"Antidepressant medication in adults: Switching and discontinuing medication\"",
"    </a>",
"    .) The energizing effects of bupropion are similar to the stimulant drugs (",
"    <a class=\"graphic graphic_table graphicRef85673 \" href=\"mobipreview.htm?23/49/24350\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/155,156\">",
"     155,156",
"    </a>",
"    ]. However, it is contraindicated for cancer patients with CNS disorders, due to its association with increased incidence of seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/157\">",
"     157",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heterocyclic antidepressants have side-effect profiles similar to those for the TCA's [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. As noted above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/18/16678?source=see_link\">",
"     maprotiline",
"    </a>",
"    should be avoided in patients with brain tumors and patients susceptible to seizures, as seizure incidence is increased with this medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/158\">",
"     158",
"    </a>",
"    ]. Mianserin, a serotonergic antidepressant with adjuvant analgesic properties is widely used in Europe and Latin America but not available in the US. It is safe and effective for the treatment of depression in cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a drug class, the MAO inhibitors are generally considered a less desirable alternative for treating depression in the terminally ill, due to the large number of adverse interactions associated with these drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/143,160\">",
"     143,160",
"    </a>",
"    ]. Thus, MAO inhibitors are generally reserved in this patient population for those who have shown past preferential responses to them for treatment of their depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=see_link\">",
"     \"Monoamine oxidase inhibitors (MAOIs) for treating depressed adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it not a classic antidepressant, the triazolobenzodiazepine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    is a mildly effective antidepressant as well as an anxiolytic, and may be particularly useful in medically ill patients who have mixed symptoms of anxiety and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/120\">",
"     120",
"    </a>",
"    ]. A meta-analysis of randomized trials comparing alprazolam with placebo in patients with major depression (not limited to patients in the palliative care population) found greater symptom response with alprazolam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Psychostimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of psychostimulants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/44/32454?source=see_link\">",
"     dextroamphetamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"     methylphenidate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    ) for the treatment of depression in medically-ill patients is supported by small prospective controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/144,162-164\">",
"     144,162-164",
"    </a>",
"    ]. The main benefit of these agents over TCAs and SSRIs is their more rapid onset of action (often within 24 to 48 hours). (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Drug selection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Psychostimulants may also be helpful in cases where dysphoric mood is associated with opioid-related sedation, severe psychomotor slowing, and even mild cognitive impairment, because stimulants are often energizing and improve overall performance on neuropsychological testing in the medically ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/163,164\">",
"     163,164",
"    </a>",
"    ]. At relatively low doses, these medications also stimulate appetite, promote a sense of well-being, and relieve feelings of weakness and fatigue in cancer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/131\">",
"     131",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=see_link&amp;anchor=H6#H6\">",
"     \"Cancer pain management with opioids: Prevention and management of side effects\", section on 'Somnolence and mental clouding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=see_link\">",
"     \"Cancer-related fatigue: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally well-tolerated, side effects may include agitation, insomnia (particularly if administered within six to eight hours of bedtime), anxiety, and tremor. Cardiac decompensation can occur in elderly patients and in those with heart disease. Rarely, confusion or delirium may occur in elderly or cognitively impaired individuals.",
"   </p>",
"   <p>",
"    Side effects are uncommon but include headache, nausea, dry mouth, anorexia, and diarrhea.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    has less sympathomimetic effects than amphetamines and is often a good choice for older patients. However, it has been associated with a mild increase in blood pressure and should be used cautiously in people with a history of arrhythmias or heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4071?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of narcolepsy\", section on 'Modafinil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19692201\">",
"    <span class=\"h3\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open-label studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    in physically healthy patients with treatment-resistant depression have found rapid, clinically moderate to large benefits with N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine, although the long-term benefits and risks are unknown. Case reports also suggest that ketamine can rapidly improve depressive symptoms in patients with refractory depression in the setting of a terminal illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/165-170\">",
"     165-170",
"    </a>",
"    ]. However, the optimal selection of patients for this approach and the best way in which to administer ketamine in this situation is unclear. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link&amp;anchor=H92878399#H92878399\">",
"     \"Treatment of resistant depression in adults\", section on 'Investigational approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy (ECT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is rarely necessary to consider electroconvulsive therapy (ECT) for medically ill patients who have depression with psychotic features or in whom treatment with antidepressants is either ineffective or poses unacceptable side effects. ECT is safe for use in the medically ill, but its use in patients near the end of life may be inconsistent with the goal of providing noninvasive and nonintrusive comfort care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/60/38858/abstract/171\">",
"     171",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of resistant depression in adults\", section on 'Electroconvulsive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PSYCHIATRIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;When assessing and treating depression in palliative care patients, several circumstances should prompt referral to a psychiatrist for an in-depth assessment of the patient's judgment, decision-making capacity, and mood. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncertainty as to the psychiatric diagnosis",
"     </li>",
"     <li>",
"      History of a major psychiatric disorder",
"     </li>",
"     <li>",
"      Patient is suicidal or requesting assisted suicide or euthanasia",
"     </li>",
"     <li>",
"      Patient is psychotic (hallucinations, delusions) or delirious",
"     </li>",
"     <li>",
"      Patient is unresponsive to therapy with first-line antidepressants",
"     </li>",
"     <li>",
"      Significant family conflict interferes with well-being, treatment or decision-making",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to terminally ill patients who desire to hasten death is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=see_link\">",
"     \"Euthanasia and physician assisted suicide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       \"Patient information: Medical care during advanced illness (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=see_link\">",
"       \"Patient information: Advance directives (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression is the most common mental health problem encountered in palliative medicine, yet it is widely misunderstood, underdiagnosed, and undertreated. Individuals who suffer from depression are at high risk of suicide and suicidal ideation, and have an increased desire for a hastened death. Failure to diagnose and treat depression impairs the quality of life of dying patients, and adds to their burden of suffering. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Scope of the problem'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Diagnosis and screening",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed mood, sadness, grief, and anticipatory feelings of loss are appropriate responses in dying patients. Feelings of hopelessness, helplessness, worthlessness, guilt, and suicidal ideation (even mild or passive) are among the best indicators of depressive disorders in such patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful diagnostic interview is the gold standard method for assessing whether patients are clinically depressed. However, a simple single-question (\"Have you been depressed most of the time for the past two weeks?\") and other abbreviated screening methods appear to be as effective as longer instruments in identifying those patients who require further assessment for depression. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Tools for assessment and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Major depression in terminally-ill patients is treatable. The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Supportive psychotherapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker. While supportive therapy may be sufficient to treat depression, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Psychosocial interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinicians should have a low threshold to initiate pharmacologic treatment, even if the diagnosis of a depressive syndrome is in question, because both psychostimulants and newer drugs such as selective serotonin receptor inhibitors (SSRIs) are relatively safe, effective, and well tolerated. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For moderately to severely depressed patients who have an estimated life expectancy of at least two to four months, we recommend both pharmacotherapy and psychotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients whose life expectancy is at least two to four months, we typically initiate therapy with an antidepressant and choose a selective serotonin receptor inhibitor rather than a tricyclic antidepressant because of their wider safety margin. Patients with more acute depressive symptoms may also benefit from use of a psychostimulant. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Drug selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Selective serotonin reuptake inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with a shorter life expectancy (less than two to four months), or who need urgent treatment, we suggest a psychostimulant rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who have an estimated life expectancy of longer than two to four months, an SSRI is then started, and the dose gradually titrated upwards, while the dose of the psychostimulant is gradually reduced. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Drug selection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regardless of the initial agent chosen, the starting dose should be approximately one-half that used in non-terminally ill patients, and then slowly and carefully titrated. During this time, maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated, and reassures the patient that he or she will not be abandoned throughout the course of the terminal illness. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Supportive psychotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the indications for referral to a psychiatrist are the following: (see",
"      <a class=\"local\" href=\"#H33\">",
"       'Indications for psychiatric referral'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Uncertainty as to the psychiatric diagnosis",
"     </li>",
"     <li>",
"      History of a major psychiatric disorder",
"     </li>",
"     <li>",
"      Patients is suicidal or requesting assisted suicide or euthanasia",
"     </li>",
"     <li>",
"      Patient is psychotic (hallucinations, delusions) or delirious",
"     </li>",
"     <li>",
"      Patient is unresponsive to therapy with first-line antidepressants",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/1\">",
"      Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/2\">",
"      Sharpe M, Strong V, Allen K, et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 2004; 90:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/3\">",
"      Lloyd-Williams M, Friedman T, Rudd N. A survey of antidepressant prescribing in the terminally ill. Palliat Med 1999; 13:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/4\">",
"      O'Mahony S, Goulet J, Kornblith A, et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage 2005; 29:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/5\">",
"      Meyer HA, Sinnott C, Seed PT. Depressive symptoms in advanced cancer. Part 2. Depression over time; the role of the palliative care professional. Palliat Med 2003; 17:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/6\">",
"      Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/7\">",
"      Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/8\">",
"      Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med 2000; 132:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/9\">",
"      Wilson KG, Chochinov HM, McPherson CJ, et al. Suffering with advanced cancer. J Clin Oncol 2007; 25:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/10\">",
"      Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 1999; 354:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/11\">",
"      Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/12\">",
"      Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/13\">",
"      Hinton J. Which patients with terminal cancer are admitted from home care? Palliat Med 1994; 8:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/14\">",
"      Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med 1994; 9:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/15\">",
"      Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002; 57:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/16\">",
"      Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/17\">",
"      Tiernan E, Casey P, O'Boyle C, et al. Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer. J R Soc Med 2002; 95:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/18\">",
"      Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer 2002; 95:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/19\">",
"      Akechi T, Okuyama T, Sugawara Y, et al. Suicidality in terminally ill Japanese patients with cancer. Cancer 2004; 100:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/20\">",
"      Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000; 284:2907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/21\">",
"      Breitbart W. Suicide in cancer patients. Oncology (Williston Park) 1987; 1:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/22\">",
"      Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry 1995; 152:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/23\">",
"      Breitbart W, Rosenfeld B, Gibson C, et al. Impact of treatment for depression on desire for hastened death in patients with advanced AIDS. Psychosomatics 2010; 51:98.",
"     </a>",
"    </li>",
"    <li>",
"     Breitbart W. Cancer Pain and Suicide. In: Cancer Pain and Suicide, Foley K, et al (Eds), Raven Press, New Jersey 1990. Vol 16, p.399.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/25\">",
"      Beck AT, Kovacs M, Weissman A. Hopelessness and suicidal behavior. An overview. JAMA 1975; 234:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/26\">",
"      Kovacs M, Beck AT, Weissman A. Hopelessness: an indicator of suicidal risk. Suicide 1975; 5:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/27\">",
"      Abbey JG, Rosenfeld B, Pessin H, Breitbart W. Hopelessness at the end of life: the utility of the hopelessness scale with terminally ill cancer patients. Br J Health Psychol 2006; 11:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/28\">",
"      Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000; 284:2460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/29\">",
"      Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/30\">",
"      Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/31\">",
"      Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994; 151:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/32\">",
"      Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; :57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/33\">",
"      McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/34\">",
"      Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004; 22:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/35\">",
"      Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/36\">",
"      Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984; 46:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/37\">",
"      Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl 4:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/38\">",
"      Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology 2001; 10:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/39\">",
"      Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 1990; 147:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/40\">",
"      Power D, Kelly S, Gilsenan J, et al. Suitable screening tests for cognitive impairment and depression in the terminally ill--a prospective prevalence study. Palliat Med 1993; 7:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/41\">",
"      Chochinov HM, Tataryn DJ, Wilson KG, et al. Prognostic awareness and the terminally ill. Psychosomatics 2000; 41:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/42\">",
"      Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/43\">",
"      Cohen LM, Dobscha SK, Hails KC, et al. Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis. Psychosom Med 2002; 64:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/44\">",
"      Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/45\">",
"      Lieberman A. Depression in Parkinson's disease -- a review. Acta Neurol Scand 2006; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/46\">",
"      Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002; 159:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/47\">",
"      Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/48\">",
"      Gibbs JS, McCoy AS, Gibbs LM, et al. Living with and dying from heart failure: the role of palliative care. Heart 2002; 88 Suppl 2:ii36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/49\">",
"      Selwyn PA, Rivard M, Kappell D, et al. Palliative care for AIDS at a large urban teaching hospital: program description and preliminary outcomes. J Palliat Med 2003; 6:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/50\">",
"      Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/51\">",
"      Harrison J, Maguire P. Predictors of psychiatric morbidity in cancer patients. Br J Psychiatry 1994; 165:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/52\">",
"      Matulonis UA. End of life issues in older patients. Semin Oncol 2004; 31:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/53\">",
"      Carroll BT, Kathol RG, Noyes R Jr, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993; 15:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/54\">",
"      Kathol RG, Noyes R Jr, Williams J, et al. Diagnosing depression in patients with medical illness. Psychosomatics 1990; 31:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/55\">",
"      Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 42:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/56\">",
"      Noyes R Jr, Kathol RG, Debelius-Enemark P, et al. Distress associated with cancer as measured by the illness distress scale. Psychosomatics 1990; 31:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/57\">",
"      Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/58\">",
"      DeFlorio, ML, Massie, MJ. Review of depression in cancer: gender differences. Depression 1995; 3:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/59\">",
"      Hughes JE. Depressive illness and lung cancer. I. Depression before diagnosis. Eur J Surg Oncol 1985; 11:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/60\">",
"      Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/61\">",
"      Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: does pain make a difference? J Pain Symptom Manage 1995; 10:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/62\">",
"      Chochinov HM, Wilson KG. The euthanasia debate: attitudes, practices and psychiatric considerations. Can J Psychiatry 1995; 40:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/63\">",
"      Spiegel D, Bloom JR. Pain in metastatic breast cancer. Cancer 1983; 52:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/64\">",
"      Wilson KG, Chochinov HM. Physician-assisted suicide. N Engl J Med 1996; 335:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/65\">",
"      Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994; 74:2570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/66\">",
"      Boyd AD, Riba M. Depression and pancreatic cancer. J Natl Compr Canc Netw 2007; 5:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/67\">",
"      Shakin EJ, Holland J. Depression and pancreatic cancer. J Pain Symptom Manage 1988; 3:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/68\">",
"      Mainio A, Hakko H, Niemel&auml; A, et al. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/69\">",
"      Litofsky NS, Farace E, Anderson F Jr, et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004; 54:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/70\">",
"      Weitzner MA, Kanfer S, Booth-Jones M. Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci 2005; 17:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/71\">",
"      Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing's syndrome and depression--a prospective study of 26 patients. Br J Psychiatry 1983; 142:16.",
"     </a>",
"    </li>",
"    <li>",
"     Breitbart W. Endocrine-related psychiatric disorders. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, New York 1989. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/73\">",
"      Brown JH, Paraskevas F. Cancer and depression: cancer presenting with depressive illness: an autoimmune disease? Br J Psychiatry 1982; 141:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/74\">",
"      Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/75\">",
"      Devlen J, Maguire P, Phillips P, et al. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987; 295:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/76\">",
"      Devlen J, Maguire P, Phillips P, Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 1987; 295:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/77\">",
"      Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/78\">",
"      Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res 1974; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/79\">",
"      Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/80\">",
"      Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/81\">",
"      Weddington WW Jr. Delirium and depression associated with amphotericin B. Psychosomatics 1982; 23:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/82\">",
"      Kelly C, Paleri V, Downs C, Shah R. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg 2007; 136:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/83\">",
"      Irwin PH, Kramer S, Diamond NH, et al. Sex differences in psychological distress during definitive radiation therapy for cancer. J Psychosoc Oncol 1986; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/84\">",
"      Sehlen S, Lenk M, Herschbach P, et al. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck 2003; 25:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/85\">",
"      Kohda R, Otsubo T, Kuwakado Y, et al. Prospective studies on mental status and quality of life in patients with head and neck cancer treated by radiation. Psychooncology 2005; 14:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/86\">",
"      Armstrong CL, Gyato K, Awadalla AW, et al. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/87\">",
"      Boston P, Bruce A, Schreiber R. Existential suffering in the palliative care setting: an integrated literature review. J Pain Symptom Manage 2011; 41:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/88\">",
"      Nelson CJ, Rosenfeld B, Breitbart W, Galietta M. Spirituality, religion, and depression in the terminally ill. Psychosomatics 2002; 43:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/89\">",
"      Labisi O. Assessing for suicide risk in depressed geriatric cancer patients. J Psychosoc Oncol 2006; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/91\">",
"      Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53:2243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/92\">",
"      Block SD. Psychological issues in end-of-life care. J Palliat Med 2006; 9:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/93\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/94\">",
"      Kroenke, K, Spitzer, RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/95\">",
"      Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/96\">",
"      Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/97\">",
"      Chochinov HM, Wilson KG, Enns M, Lander S. \"Are you depressed?\" Screening for depression in the terminally ill. Am J Psychiatry 1997; 154:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/98\">",
"      Lees N, Lloyd-Williams M. Assessing depression in palliative care patients using the visual analogue scale: a pilot study. Eur J Cancer Care (Engl) 1999; 8:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/99\">",
"      Periyakoil VS, Kraemer HC, Noda A, et al. The development and initial validation of the Terminally Ill Grief or Depression Scale (TIGDS). Int J Methods Psychiatr Res 2005; 14:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/100\">",
"      Lloyd-Williams M, Spiller J, Ward J. Which depression screening tools should be used in palliative care? Palliat Med 2003; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/101\">",
"      Holtom N, Barraclough J. Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care? Palliat Med 2000; 14:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/102\">",
"      Lloyd-Williams M, Dennis M, Taylor F. A prospective study to compare three depression screening tools in patients who are terminally ill. Gen Hosp Psychiatry 2004; 26:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/103\">",
"      Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/104\">",
"      Jefford M, Mileshkin L, Richards K, et al. Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients. Br J Cancer 2004; 91:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/105\">",
"      Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/106\">",
"      Robinson JA, Crawford GB. Identifying palliative care patients with symptoms of depression: an algorithm. Palliat Med 2005; 19:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/107\">",
"      Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/108\">",
"      Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care 1991; 29:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/109\">",
"      Thekkumpurath P, Venkateswaran C, Kumar M, Bennett MI. Screening for psychological distress in palliative care: a systematic review. J Pain Symptom Manage 2008; 36:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/110\">",
"      Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer 2008; 98:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/111\">",
"      Mahoney J, Drinka TJ, Abler R, et al. Screening for depression: single question versus GDS. J Am Geriatr Soc 1994; 42:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/112\">",
"      Watkins C, Daniels L, Jack C, et al. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. BMJ 2001; 323:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/113\">",
"      Lloyd-Williams M, Dennis M, Taylor F, Baker I. Is asking patients in palliative care, \"are you depressed?\" Appropriate? Prospective study. BMJ 2003; 327:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/114\">",
"      Akechi T, Okuyama T, Sugawara Y, et al. Screening for depression in terminally ill cancer patients in Japan. J Pain Symptom Manage 2006; 31:5.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/116\">",
"      A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/117\">",
"      Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 1981; 38:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/118\">",
"      Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983; 45:333.",
"     </a>",
"    </li>",
"    <li>",
"     Massie MJ, Holland JC, Straker N. Psychotherapeutic interventions. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, New York 1989. p.455.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/120\">",
"      Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991; 9:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/121\">",
"      Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr 2004; :105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/122\">",
"      Ly KL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 2002; 16:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/123\">",
"      Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999; 80:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/124\">",
"      Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst 2002; 94:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/125\">",
"      Devine EC, Westlake SK. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum 1995; 22:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/126\">",
"      Meyer TJ, Mark MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol 1995; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/127\">",
"      Stagg EK, Lazenby M. Best practices for the nonpharmacological treatment of depression at the end of life. Am J Hosp Palliat Care 2012; 29:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/128\">",
"      Akechi T, Okuyama T, Onishi J, et al. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev 2008; :CD005537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/129\">",
"      Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-based depression treatment in older adults: a randomized controlled trial. JAMA 2004; 291:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/130\">",
"      Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004; 291:1081.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson KG, Chochinov HM, de Faye BJ, Breitbart W. and Management of Depression in Palliative Care. In: Handbook of Psychiatry in Palliative Medicine, Chochinov HM, Breitbart W (Eds), Oxford University Press, New York 2000. p.2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/132\">",
"      Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23:5520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/133\">",
"      Montross L, Winters KD, Irwin SA. Dignity therapy implementation in a community-based hospice setting. J Palliat Med 2011; 14:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/134\">",
"      Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol 2011; 12:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/135\">",
"      Greenstein M, Breitbart W. Cancer and the experience of meaning: a group psychotherapy program for people with cancer. Am J Psychother 2000; 54:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/136\">",
"      Breitbart W, Poppito S, Rosenfeld B, et al. Pilot randomized controlled trial of individual meaning-centered psychotherapy for patients with advanced cancer. J Clin Oncol 2012; 30:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/137\">",
"      Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010; :CD007503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/138\">",
"      Rayner L, Price A, Evans A, et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 2011; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/139\">",
"      Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/140\">",
"      Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/141\">",
"      Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/142\">",
"      Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 2011; 47:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/143\">",
"      Burns MM, Eisendrath SJ. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics 1994; 35:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/144\">",
"      Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/145\">",
"      Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/146\">",
"      Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003; 21:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/147\">",
"      Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998; 7:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/148\">",
"      Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/149\">",
"      Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51:126.",
"     </a>",
"    </li>",
"    <li>",
"     Breitbart W, Passik SD. Psychiatric aspects of palliative care. In: Oxford Textbook of Palliative Medicine, Doyle D, Hanks GW, MacDonald (Eds), Oxford University Press, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/151\">",
"      Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/152\">",
"      Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/153\">",
"      Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/154\">",
"      Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/155\">",
"      Shopsin B. Bupropion: a new clinical profile in the psychobiology of depression. J Clin Psychiatry 1983; 44:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/156\">",
"      Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/157\">",
"      Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/158\">",
"      Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 1986; 43:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/159\">",
"      van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 1996; 169:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/160\">",
"      Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 Suppl:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/161\">",
"      van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012; 7:CD007139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/162\">",
"      Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987; 28:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/163\">",
"      Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/164\">",
"      Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002; 20:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/165\">",
"      Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 2012; 15:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/166\">",
"      Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine \"burst\" for refractory depression in a patient with advanced cancer. J Palliat Med 2008; 11:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/167\">",
"      Yang C, Zhou ZQ, Yang JJ. Be prudent of ketamine in treating resistant depression in patients with cancer. J Palliat Med 2011; 14:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/168\">",
"      Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med 2010; 13:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/169\">",
"      Kollmar R, Markovic K, Th&uuml;rauf N, et al. Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 2008; 42:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/170\">",
"      Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 2010; 13:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/60/38858/abstract/171\">",
"      Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry 1990; 51 Suppl:12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2205 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-37CB1B5951-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38858=[""].join("\n");
var outline_f37_60_38858=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCOPE OF THE PROBLEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Burden of depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Depression, suicide, and desire for a hastened death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevalence of depression in palliative care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Cancer patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Non-cancer populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Age and gender",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prior history of depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Uncontrolled symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Type of illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Illness and treatment-related factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Existential concerns and spirituality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASSESSMENT AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tools for assessment and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Criterion-based diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Self-report instruments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Simple screening instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      General treatment principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Psychosocial interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Supportive psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Structured cognitive therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Existential psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Drug selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Tricyclic antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Other antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Psychostimulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19692201\">",
"      - Ketamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Electroconvulsive therapy (ECT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      INDICATIONS FOR PSYCHIATRIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/2205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2205|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/45/35537\" title=\"figure 1\">",
"      Symptoms in the last six months of life in cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/2205|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/49/16155\" title=\"table 1\">",
"      Diagn approach depres CA pt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/46/36587\" title=\"table 2\">",
"      Characteristic grief depres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/63/1021\" title=\"table 3\">",
"      Resrch meth depres term ill",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/14/1260\" title=\"table 4\">",
"      DSMIV Endicott sympt depres",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/12/14541\" title=\"table 5\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/53/29531\" title=\"table 6\">",
"      Abbrev screen depres cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/49/24350\" title=\"table 7\">",
"      Stimulants and antidepressants - palliative care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/46/38639\" title=\"table 8\">",
"      Side effects antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/32/42508\" title=\"table 9\">",
"      Anticholinergic risk scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/33/26135?source=related_link\">",
"      Antidepressant medication in adults: Switching and discontinuing medication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41178?source=related_link\">",
"      Approach to symptom assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/58/7077?source=related_link\">",
"      Assessment of cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9290?source=related_link\">",
"      Cancer pain management with opioids: Prevention and management of side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27098?source=related_link\">",
"      Cancer-related fatigue: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16601?source=related_link\">",
"      Depression in adults: Supportive psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/13/12504?source=related_link\">",
"      Depression, mania, and schizophrenia in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/12/24778?source=related_link\">",
"      Euthanasia and physician assisted suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/1/27673?source=related_link\">",
"      Management of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/25/7574?source=related_link\">",
"      Monoamine oxidase inhibitors (MAOIs) for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/52/28490?source=related_link\">",
"      Overview of comprehensive patient assessment in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/7/35962?source=related_link\">",
"      Overview of managing common non-pain symptoms in palliative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5831?source=related_link\">",
"      Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/6/29801?source=related_link\">",
"      Palliative care: Benefits, services, and models of care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/53/36694?source=related_link\">",
"      Palliative care: End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/61/25554?source=related_link\">",
"      Patient information: Advance directives (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29769?source=related_link\">",
"      Psychosocial issues at the end of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41208?source=related_link\">",
"      Religion, spirituality, and end of life care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4071?source=related_link\">",
"      Treatment of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/20/36169?source=related_link\">",
"      Unipolar depression in adults and tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_60_38859="Evaluation for transtracheal O2";
var content_f37_60_38859=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient evaluation for transtracheal oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rationale/decision making",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is patient receiving optimal therapy?",
"       </td>",
"       <td>",
"        If not, optimize and reevaluate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is disease process/O",
"        <sub>",
"         2",
"        </sub>",
"        requirement relatively stable or rapidly progressing suggesting a preterminal phase?",
"       </td>",
"       <td>",
"        If patient is in a preterminal phase of the disease, benefits of transtracheal oxygen (TTO) may be short-term. TTO care may add to family burden, rather than help.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        What PaO",
"        <sub>",
"         2",
"        </sub>",
"        is achieved with 100 percent O",
"        <sub>",
"         2",
"        </sub>",
"        ?",
"       </td>",
"       <td>",
"        Evaluate ability of 100 percent O",
"        <sub>",
"         2",
"        </sub>",
"        to raise PaO",
"        <sub>",
"         2",
"        </sub>",
"        . If 100 percent O",
"        <sub>",
"         2",
"        </sub>",
"        does not increase the PaO",
"        <sub>",
"         2",
"        </sub>",
"        , TTO is not indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can the patient walk?",
"       </td>",
"       <td>",
"        Ability to walk without severe decompensation typically indicates sufficient airflow to clear mucus balls with coughing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can periodic stripping be done, if needed?",
"       </td>",
"       <td>",
"        High TTO flows promote formation of mucus balls on the outside of the catheter. Airway obstruction can occur if this mucus is not removed by coughing or stripping. High-flow patients should have their catheter stripped (removed over guide wire) at periodic intervals to assess risk of mucus ball formation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38859=[""].join("\n");
var outline_f37_60_38859=null;
var title_f37_60_38860="Maternal age aneuploidy risk";
var content_f37_60_38860=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Crude maternal age-specific rates for trisomy 21, Down syndrome, and all chromosome abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       Maternal age, years",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Data from live births",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Data from 2nd trimester amniocentesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Trisomy 21",
"      </td>",
"      <td class=\"subtitle2\">",
"       All chromosome abnormalities",
"      </td>",
"      <td class=\"subtitle2\">",
"       Trisomy 21",
"      </td>",
"      <td class=\"subtitle2\">",
"       All chromosome abnormalities",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       1/625",
"      </td>",
"      <td>",
"       1/345",
"      </td>",
"      <td>",
"       1/416",
"      </td>",
"      <td>",
"       1/208",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       34",
"      </td>",
"      <td>",
"       1/500",
"      </td>",
"      <td>",
"       1/277",
"      </td>",
"      <td>",
"       1/333",
"      </td>",
"      <td>",
"       1/151",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       1/385",
"      </td>",
"      <td>",
"       1/204",
"      </td>",
"      <td>",
"       1/250",
"      </td>",
"      <td>",
"       1/132",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       1/303",
"      </td>",
"      <td>",
"       1/167",
"      </td>",
"      <td>",
"       1/192",
"      </td>",
"      <td>",
"       1/105",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       1/227",
"      </td>",
"      <td>",
"       1/130",
"      </td>",
"      <td>",
"       1/149",
"      </td>",
"      <td>",
"       1/83",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       38",
"      </td>",
"      <td>",
"       1/175",
"      </td>",
"      <td>",
"       1/103",
"      </td>",
"      <td>",
"       1/115",
"      </td>",
"      <td>",
"       1/65",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       39",
"      </td>",
"      <td>",
"       1/137",
"      </td>",
"      <td>",
"       1/81",
"      </td>",
"      <td>",
"       1/89",
"      </td>",
"      <td>",
"       1/53",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       1/106",
"      </td>",
"      <td>",
"       1/63",
"      </td>",
"      <td>",
"       1/69",
"      </td>",
"      <td>",
"       1/40",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       41",
"      </td>",
"      <td>",
"       1/81",
"      </td>",
"      <td>",
"       1/50",
"      </td>",
"      <td>",
"       1/53",
"      </td>",
"      <td>",
"       1/31",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       42",
"      </td>",
"      <td>",
"       1/64",
"      </td>",
"      <td>",
"       1/39",
"      </td>",
"      <td>",
"       1/41",
"      </td>",
"      <td>",
"       1/25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       1/50",
"      </td>",
"      <td>",
"       1/30",
"      </td>",
"      <td>",
"       1/31",
"      </td>",
"      <td>",
"       1/19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       44",
"      </td>",
"      <td>",
"       1/38",
"      </td>",
"      <td>",
"       1/24",
"      </td>",
"      <td>",
"       1/25",
"      </td>",
"      <td>",
"       1/15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       45",
"      </td>",
"      <td>",
"       1/30",
"      </td>",
"      <td>",
"       1/19",
"      </td>",
"      <td>",
"       1/19",
"      </td>",
"      <td>",
"       1/12",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schreinemachers, DM, Cross, PK, Hook, EB. Rates of trisomies 21, 18, 13 and other chromosome abnormalities in about 20,000 prenatal studies compared with estimated rates in live births. Hum Genet 1982; 61:318.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38860=[""].join("\n");
var outline_f37_60_38860=null;
var title_f37_60_38861="Contents: Cutaneous lymphoma";
var content_f37_60_38861=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cutaneous lymphoma",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cutaneous lymphoma",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/47/25337\">",
"           Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/36/35400\">",
"           Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/23/7546\">",
"           Lymphomatoid papulosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/46/20200\">",
"           Parapsoriasis (small plaque and large plaque parapsoriasis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/6/15464\">",
"           Primary cutaneous follicle center lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/49/26391\">",
"           Primary cutaneous large B cell lymphoma, leg type",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/9/26776\">",
"           Primary cutaneous marginal zone lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/35/36410\">",
"           Treatment of advanced stage (IIB to IV) mycosis fungoides and Szary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/39/17017\">",
"           Treatment of early stage (IA to IIA) mycosis fungoides",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-2A36FFA5A1-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_60_38861=[""].join("\n");
var outline_f37_60_38861=null;
var title_f37_60_38862="Edge detection angiography";
var content_f37_60_38862=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Edge detection on quantitative coronary angiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Using the image obtained from the contrast angiogram, the minimal luminal diameter is measured and compared to the diameter of the \"normal\" vessel immediately adjacent which serves as the reference diameter. The percent stenosis can then be calculated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38862=[""].join("\n");
var outline_f37_60_38862=null;
var title_f37_60_38863="X-ray of sacroiliitis and hip injury in adult patient with psJIA";
var content_f37_60_38863=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiograph of sacroiliitis and hip injury in adult patient with juvenile-onset psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mild unilateral sacroiliitis and marked left &gt; right hip injury in an adult patient with juvenile-onset psoriatic arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_60_38863=[""].join("\n");
var outline_f37_60_38863=null;
